<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Pathog</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Pathog</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plospath</journal-id><journal-title-group><journal-title>PLoS Pathogens</journal-title></journal-title-group><issn pub-type="ppub">1553-7366</issn><issn pub-type="epub">1553-7374</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5933708</article-id><article-id pub-id-type="doi">10.1371/journal.ppat.1006965</article-id><article-id pub-id-type="publisher-id">PPATHOGENS-D-17-01025</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>Viremia</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Disease Vectors</subject><subj-group><subject>Insect Vectors</subject><subj-group><subject>Mosquitoes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Species Interactions</subject><subj-group><subject>Disease Vectors</subject><subj-group><subject>Insect Vectors</subject><subj-group><subject>Mosquitoes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Eukaryota</subject><subj-group><subject>Animals</subject><subj-group><subject>Invertebrates</subject><subj-group><subject>Arthropoda</subject><subj-group><subject>Insects</subject><subj-group><subject>Mosquitoes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>Dengue Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>Dengue Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>Dengue Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>Dengue Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Infectious Disease Control</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immunity</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immunity</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Vector-Borne Diseases</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Geographical Locations</subject><subj-group><subject>Asia</subject><subj-group><subject>Thailand</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Contributions from the silent majority dominate dengue virus transmission</article-title><alt-title alt-title-type="running-head">Silent infections dominate dengue transmission</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5227-1406</contrib-id><name><surname>ten Bosch</surname><given-names>Quirine A.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="author-notes" rid="currentaff001"><sup>&#x000a4;a</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2531-161X</contrib-id><name><surname>Clapham</surname><given-names>Hannah E.</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="author-notes" rid="currentaff002"><sup>&#x000a4;b</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5958-2138</contrib-id><name><surname>Lambrechts</surname><given-names>Louis</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Duong</surname><given-names>Veasna</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1372-3008</contrib-id><name><surname>Buchy</surname><given-names>Philippe</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Althouse</surname><given-names>Benjamin M.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff007"><sup>7</sup></xref><xref ref-type="aff" rid="aff008"><sup>8</sup></xref><xref ref-type="aff" rid="aff009"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lloyd</surname><given-names>Alun L.</given-names></name><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff010"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name><surname>Waller</surname><given-names>Lance A.</given-names></name><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff011"><sup>11</sup></xref></contrib><contrib contrib-type="author"><name><surname>Morrison</surname><given-names>Amy C.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff012"><sup>12</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kitron</surname><given-names>Uriel</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff013"><sup>13</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0710-270X</contrib-id><name><surname>Vazquez-Prokopec</surname><given-names>Gonzalo M.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff013"><sup>13</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2947-8123</contrib-id><name><surname>Scott</surname><given-names>Thomas W.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff012"><sup>12</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7518-4014</contrib-id><name><surname>Perkins</surname><given-names>T. Alex</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, IN, United States</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, United States</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Insect-Virus Interactions Group, Department of Genomes and Genetics, Institut Pasteur, Paris, France</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Centre National de la Recherche Scientifique, Unit&#x000e9; Mixte de Recherche 2000, Paris, France</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Virology Unit, Institut Pasteur du Cambodge, Institut Pasteur International Network, Phnom Penh, Cambodia</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>GlaxoSmithKline, Vaccines R&#x00026;D, Singapore</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Institute for Disease Modeling, Bellevue, WA, United States</addr-line></aff><aff id="aff008"><label>8</label>
<addr-line>Information School, University of Washington, Seattle, WA, United States</addr-line></aff><aff id="aff009"><label>9</label>
<addr-line>Department of Biology, New Mexico State University, Las Cruces, NM, United States</addr-line></aff><aff id="aff010"><label>10</label>
<addr-line>Department of Mathematics, Biomathematics Graduate Program and Center for Quantitative Sciences in Biomedicine, North Carolina State University, Raleigh, NC, United States</addr-line></aff><aff id="aff011"><label>11</label>
<addr-line>Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, United States</addr-line></aff><aff id="aff012"><label>12</label>
<addr-line>Department of Entomology and Nematology, University of California, Davis, CA, United States</addr-line></aff><aff id="aff013"><label>13</label>
<addr-line>Department of Environmental Sciences, Emory University, Atlanta, GA, United States</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Ferguson</surname><given-names>Neil M.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Imperial College London, UNITED KINGDOM</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p>I have read the journal's policy and the authors of the manuscript have the following competing interests: QAtB and TAP receive support from GlaxoSmithKline for unrelated work on dengue vaccine modeling. Philippe Buchy is currently an employee of GlaxoSmithKline vaccines.</p></fn><fn fn-type="current-aff" id="currentaff001"><label>&#x000a4;a</label><p>Current address: Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Paris, France, CNRS UMR2000: G&#x000e9;nomique &#x000e9;volutive, mod&#x000e9;lisation et sant&#x000e9; (GEMS), Institut Pasteur, Paris, Center of Bioinformatics, Biostatistics and Integrative Biology, Institut Pasteur, Paris, France</p></fn><fn fn-type="current-aff" id="currentaff002"><label>&#x000a4;b</label><p>Current address: Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, England</p></fn><corresp id="cor001">* E-mail: <email>quirine.ten-bosch@pasteur.fr</email> (QAtB); <email>taperkins@nd.edu</email> (TAP)</corresp></author-notes><pub-date pub-type="epub"><day>3</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2018</year></pub-date><volume>14</volume><issue>5</issue><elocation-id>e1006965</elocation-id><history><date date-type="received"><day>13</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>9</day><month>3</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 ten Bosch et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>ten Bosch et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="ppat.1006965.pdf"/><abstract><p>Despite estimates that, each year, as many as 300 million dengue virus (DENV) infections result in either no perceptible symptoms (asymptomatic) or symptoms that are sufficiently mild to go undetected by surveillance systems (inapparent), it has been assumed that these infections contribute little to onward transmission. However, recent blood-feeding experiments with <italic>Aedes aegypti</italic> mosquitoes showed that people with asymptomatic and pre-symptomatic DENV infections are capable of infecting mosquitoes. To place those findings into context, we used models of within-host viral dynamics and human demographic projections to (1) quantify the net infectiousness of individuals across the spectrum of DENV infection severity and (2) estimate the fraction of transmission attributable to people with different severities of disease. Our results indicate that net infectiousness of people with asymptomatic infections is 80% (median) that of people with apparent or inapparent symptomatic infections (95% credible interval (CI): 0&#x02013;146%). Due to their numerical prominence in the infectious reservoir, clinically inapparent infections in total could account for 84% (CI: 82&#x02013;86%) of DENV transmission. Of infections that ultimately result in any level of symptoms, we estimate that 24% (95% CI: 0&#x02013;79%) of onward transmission results from mosquitoes biting individuals during the pre-symptomatic phase of their infection. Only 1% (95% CI: 0.8&#x02013;1.1%) of DENV transmission is attributable to people with clinically detected infections after they have developed symptoms. These findings emphasize the need to (1) reorient current practices for outbreak response to adoption of pre-emptive strategies that account for contributions of undetected infections and (2) apply methodologies that account for undetected infections in surveillance programs, when assessing intervention impact, and when modeling mosquito-borne virus transmission.</p></abstract><abstract abstract-type="summary"><title>Author summary</title><p>Most dengue virus infections result in either no perceptible symptoms or symptoms that are so mild that they go undetected by surveillance systems. It is unclear how much these infections contribute to the overall transmission and burden of dengue. At an individual level, we show that people with asymptomatic infections are approximately 80% as infectious to mosquitoes as their symptomatic counterparts. At a population level, we show that approximately 88% of infections result from people who display no apparent symptoms at the time of transmission. These results suggest that individuals undetected by surveillance systems may be the primary reservoir of dengue virus transmission and that policy for dengue control and prevention must be revised accordingly.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>P01AI098670</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2947-8123</contrib-id><name><surname>Scott</surname><given-names>Thomas W.</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>ANR-10- LABX-62-IBEID</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5958-2138</contrib-id><name><surname>Lambrechts</surname><given-names>Louis</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01-AI091980</award-id><principal-award-recipient><name><surname>Lloyd</surname><given-names>Alun L.</given-names></name></principal-award-recipient></award-group><award-group id="award004"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>RTG/DMS - 1246991</award-id><principal-award-recipient><name><surname>Lloyd</surname><given-names>Alun L.</given-names></name></principal-award-recipient></award-group><award-group id="award005"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>5R01AI102939-03</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2531-161X</contrib-id><name><surname>Clapham</surname><given-names>Hannah E.</given-names></name></principal-award-recipient></award-group><award-group id="award006"><funding-source><institution>European Union Seventh Framework Programme</institution></funding-source><award-id>FP7/2007/2011</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5958-2138</contrib-id><name><surname>Lambrechts</surname><given-names>Louis</given-names></name></principal-award-recipient></award-group><award-group id="award007"><funding-source><institution>City of Paris Emergence(s) program in Biomedical Research</institution></funding-source><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5958-2138</contrib-id><name><surname>Lambrechts</surname><given-names>Louis</given-names></name></principal-award-recipient></award-group><funding-statement>This research was funded by a grant from the US National Institutes of Health &#x02013; National Institute of Allergy and Infectious Diseases (NIH/NIAID (<ext-link ext-link-type="uri" xlink:href="https://www.niaid.nih.gov/">https://www.niaid.nih.gov/</ext-link>)) award number P01AI098670 (to TWS). Research leading to results on infectiousness in asymptomatic individuals received funding from the European Union Seventh Framework Programme (FP7/2007/2011) under Grant Agreement 282 378. LL is supported by the French Government&#x02019;s Investissement d&#x02019;Avenir program, Laboratoire d&#x02019;Excellence Integrative Biology of Emerging Infectious Diseases (grant ANR-10-LABX-62-IBEID (<ext-link ext-link-type="uri" xlink:href="http://www.agence-nationale-recherche.fr/">http://www.agence-nationale-recherche.fr/</ext-link>)) and the City of Paris (<ext-link ext-link-type="uri" xlink:href="http://www.paris.fr/">http://www.paris.fr/</ext-link>) Emergence(s) program in Biomedical Research. BMA thanks Bill and Melinda Gates through the Global Good Fund (<ext-link ext-link-type="uri" xlink:href="http://www.globalgoodfund.org/">http://www.globalgoodfund.org/</ext-link>). QAtB, BMA and TAP received support from Intellectual Ventures (<ext-link ext-link-type="uri" xlink:href="http://www.intellectualventures.com/">http://www.intellectualventures.com/</ext-link>). ALL is supported by grant R01-AI091980 from the National Institutes of Health (<ext-link ext-link-type="uri" xlink:href="http://www.nih.gov/">www.nih.gov/</ext-link>) and by the National Science Foundation (<ext-link ext-link-type="uri" xlink:href="http://www.nsf.gov">www.nsf.gov</ext-link>) (RTG/DMS - 1246991). HEC is supported by National Institutes of Health (<ext-link ext-link-type="uri" xlink:href="http://www.nih.gov/">www.nih.gov/</ext-link>) under award no. 5R01AI102939-03. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="0"/><page-count count="20"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All codes and data to reproduce analyses in this manuscript and its supplements are available from the Open Science Framework database (<ext-link ext-link-type="uri" xlink:href="https://osf.io/pjbhz/">https://osf.io/pjbhz/</ext-link>) and <ext-link ext-link-type="uri" xlink:href="https://github.com">github.com</ext-link> (<ext-link ext-link-type="uri" xlink:href="https://github.com/quirine/SilentMajority">https://github.com/quirine/SilentMajority</ext-link>).</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All codes and data to reproduce analyses in this manuscript and its supplements are available from the Open Science Framework database (<ext-link ext-link-type="uri" xlink:href="https://osf.io/pjbhz/">https://osf.io/pjbhz/</ext-link>) and <ext-link ext-link-type="uri" xlink:href="https://github.com">github.com</ext-link> (<ext-link ext-link-type="uri" xlink:href="https://github.com/quirine/SilentMajority">https://github.com/quirine/SilentMajority</ext-link>).</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Though often assumed benign, it is increasingly recognized that for many pathogens, clinically inapparent infections can represent a sizeable portion of the infectious reservoir [<xref rid="ppat.1006965.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="ppat.1006965.ref003" ref-type="bibr">3</xref>] and contribute substantially to pathogen transmission [<xref rid="ppat.1006965.ref004" ref-type="bibr">4</xref>]. Understanding the contribution to transmission from people with inapparent infections is fundamental for inferring drivers of transmission [<xref rid="ppat.1006965.ref003" ref-type="bibr">3</xref>], estimating the timing and scope of outbreaks [<xref rid="ppat.1006965.ref005" ref-type="bibr">5</xref>], planning and monitoring control efforts [<xref rid="ppat.1006965.ref006" ref-type="bibr">6</xref>], and assessing the feasibility of pathogen elimination [<xref rid="ppat.1006965.ref001" ref-type="bibr">1</xref>,<xref rid="ppat.1006965.ref006" ref-type="bibr">6</xref>].</p><p>Of the 390 million dengue virus (DENV) infections that occur globally each year, an estimated 300 million do not result in symptoms severe enough for a person to seek treatment [<xref rid="ppat.1006965.ref007" ref-type="bibr">7</xref>,<xref rid="ppat.1006965.ref008" ref-type="bibr">8</xref>], meaning that they likely go undetected by most surveillance systems. The four closely related DENV1-4 serotypes are transmitted predominantly by <italic>Aedes aegypti</italic> mosquitoes [<xref rid="ppat.1006965.ref009" ref-type="bibr">9</xref>], and infection with one serotype is believed to be followed by short-term, heterologous cross-immunity and life-long homologous immunity [<xref rid="ppat.1006965.ref010" ref-type="bibr">10</xref>]. Based on observed positive correlations between DENV viremia and disease severity [<xref rid="ppat.1006965.ref011" ref-type="bibr">11</xref>&#x02013;<xref rid="ppat.1006965.ref014" ref-type="bibr">14</xref>], it has been assumed that the 300 million annual clinically inapparent infections contribute little to onward transmission because their viremia levels are too low to efficiently infect mosquitoes. On the other hand, high sero-conversion rates coinciding with few reported cases in some areas suggest that inapparent infections may contribute appreciably to silent DENV transmission [<xref rid="ppat.1006965.ref015" ref-type="bibr">15</xref>]. Furthermore, recent blood-feeding experiments with <italic>Ae</italic>. <italic>aegypti</italic> mosquitoes demonstrated that people with asymptomatic and pre-symptomatic DENV infections are indeed capable of infecting mosquitoes [<xref rid="ppat.1006965.ref016" ref-type="bibr">16</xref>].</p><p>Although these indications of a possible role of inapparent infections in DENV transmission have become more evident, the proportion of overall transmission for which they are responsible is unknown. This potentially significant unknown has important implications for policy given the difficulty of identifying people with inapparent infections, which may be a critical technical limitation in the event that they contribute appreciably to transmission.</p><p>We addressed this question by estimating the net infectiousness (NI) of DENV-infected individuals with different clinical manifestations, including asymptomatic infections, and quantifying the relative contributions of these clinically distinct classes to the overall force of infection (FoI) of DENV. Our approach involved three distinct steps (<xref ref-type="fig" rid="ppat.1006965.g001">Fig 1</xref>). First, we estimated the net infectiousness of different classes of DENV infections by combining class-specific estimates of DENV viremia trajectories and class-specific estimates of the relationship between DENV viremia and infectiousness to mosquitoes. Second, we estimated the proportion of infections of each class by first quantifying the proportion of primary, secondary, and post-secondary DENV infections in a population with a given level of transmission intensity. We then translated those proportions of primary, secondary, and post-secondary infections into proportions of each infection class based on estimates of those relationships from the literature. Third, we used a novel formulation of DENV force of infection to combine estimates of individual-level net infectiousness of each infection class and estimates of the proportion of each infection class in a hypothetical population to estimate the proportional contribution of each infection class to overall DENV force of infection.</p><fig id="ppat.1006965.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1006965.g001</object-id><label>Fig 1</label><caption><title>Flowchart of methodological framework.</title><p>Our overall approach consisted of three steps, depicted in the three columns. The products of all three combine to yield our estimate of the relative contribution to overall force of infection from each infection class. Likewise, uncertainty in each component of the analysis is propagated into other components of the analysis through repeated Monte Carlo sampling, with Monte Carlo samples from one portion of the analysis flowing to others according to the arrows and providing the basis for credible intervals reported in the <italic>Results</italic> section. Details of how the sub-steps indicated in this figure were performed are described in subsections of the <italic>Materials and Methods</italic> section.</p></caption><graphic xlink:href="ppat.1006965.g001"/></fig></sec><sec sec-type="results" id="sec002"><title>Results</title><sec id="sec003"><title>Definitions</title><p>We distinguished four classes of infections (<xref ref-type="fig" rid="ppat.1006965.g002">Fig 2</xref>). We referred to the first class as &#x0201c;asymptomatic&#x0201d; (As), which we defined as people having absolutely no perceptible symptoms at any point during their infection [<xref rid="ppat.1006965.ref016" ref-type="bibr">16</xref>]. The remaining people with symptomatic (S) infections were divided into: (1) inapparent symptomatic (IS), people whose symptoms are sufficiently mild to not disrupt their daily routine and thus do not prompt healthcare seeking [<xref rid="ppat.1006965.ref007" ref-type="bibr">7</xref>,<xref rid="ppat.1006965.ref016" ref-type="bibr">16</xref>]; and (2) apparent symptomatic (AS) individuals, whose clinical presentation does disrupt their daily routine according to the WHO definition of &#x0201c;at least fever and two dengue symptoms&#x0201d; [<xref rid="ppat.1006965.ref017" ref-type="bibr">17</xref>]. Detected apparent symptomatic individuals (DAS) are identified by health surveillance systems if they seek clinical consultation and are diagnosed as a confirmed dengue case. Others remain undetected (UAS) (<xref ref-type="fig" rid="ppat.1006965.g002">Fig 2</xref>).</p><fig id="ppat.1006965.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1006965.g002</object-id><label>Fig 2</label><caption><title>Definitions of DENV infection classes.</title></caption><graphic xlink:href="ppat.1006965.g002"/></fig></sec><sec id="sec004"><title>Net infectiousness (NI)</title><p>We quantified differences in the net infectiousness to mosquitoes of individuals with As, IS, and AS infections. We modeled viral transmission dynamics of each of these infection types by using a mechanistic model of the within-host dynamics of DENV fitted to plasma viral titers over time for patients with S infections [<xref rid="ppat.1006965.ref018" ref-type="bibr">18</xref>] and adjusted these trajectories using an empirically informed distribution of correction ratios to model trajectories of As infections [<xref rid="ppat.1006965.ref016" ref-type="bibr">16</xref>]. Secondary (2&#x000b0;) infections were parameterized to exhibit faster cell entry and accelerated clearance of viral particles than primary (1&#x000b0;) infections, consistent with theory for antibody-dependent enhancement and increased activation of the immune system [<xref rid="ppat.1006965.ref018" ref-type="bibr">18</xref>]. This resulted in a shorter duration of detectable, and potentially infectious, viremia [<xref rid="ppat.1006965.ref019" ref-type="bibr">19</xref>&#x02013;<xref rid="ppat.1006965.ref021" ref-type="bibr">21</xref>]. Post-2&#x000b0; infections were excluded from consideration for our primary analysis due to a combination of low risk of apparent disease and high rates of cross-reactive antibodies for this group [<xref rid="ppat.1006965.ref022" ref-type="bibr">22</xref>]. Nonetheless, because there is no conclusive evidence about viremia of post-2&#x000b0; infections [<xref rid="ppat.1006965.ref022" ref-type="bibr">22</xref>], we performed a sensitivity analysis in which an upper limit for post-2&#x000b0; viremia was assumed similar to that of 2&#x000b0; infections given that the dynamics of both are limited by varying degrees of immunity (<xref ref-type="supplementary-material" rid="ppat.1006965.s007">S1 Fig</xref>). Next, we applied logistic regression models [<xref rid="ppat.1006965.ref016" ref-type="bibr">16</xref>] to infer infectiousness to mosquitoes from human viral titers (<xref ref-type="supplementary-material" rid="ppat.1006965.s003">S1</xref> and <xref ref-type="supplementary-material" rid="ppat.1006965.s006">S4</xref> Tables, <xref ref-type="supplementary-material" rid="ppat.1006965.s002">S2 Text</xref>) (see <italic><xref ref-type="sec" rid="sec009">Materials and Methods</xref></italic> for details).</p><p>The median NI to <italic>Ae</italic>. <italic>aegypti</italic> of As infections was lower than that of S infections, but of similar magnitude (1&#x000b0;: 87%, 95% CI: 0&#x02013;151%; 2&#x000b0;: 74%, 95% CI: 0&#x02013;137%). The median NI of 1&#x000b0; infections was greater than that of corresponding 2&#x000b0; infections (As: 140%, 95% CI: 111&#x02013;275%; S: 120%, 95% CI: 100&#x02013;235%) (<xref ref-type="fig" rid="ppat.1006965.g003">Fig 3</xref>). Approximately one quarter of the NI of S infections occurred before symptom onset (1&#x000b0;: 21%, 95% CI: 1&#x02013;56%, 2&#x000b0;: 27%, 95% CI: 0&#x02013;97%). By calculating the probability that a random draw from the NI distribution of one infection class was lower than a random draw from another class (Pr), we confirmed that As infections are more likely to be less infectious than S infections (1&#x000b0;: Pr = 0.55; 2&#x000b0;: Pr = 0.58) and 2&#x000b0; infections are more likely to be less infectious than 1&#x000b0; infections (As: Pr = 0.56; S: Pr = 0.62) (<xref ref-type="supplementary-material" rid="ppat.1006965.s004">S2 Table</xref>). There was wide variability in the NI of As infections, however, with both two-fold lesser or greater infectiousness compared to S infections appearing probable (lesser, 1&#x000b0;: 0.38, 2&#x000b0;: 0.42; greater, 1&#x000b0;: 0.16, 2&#x000b0;: 0.20). Overall, 1&#x000b0; As infections were not significantly less infectious than 2&#x000b0; S infections (Wilcoxon rank sum test, <italic>p</italic> = 0.97).</p><fig id="ppat.1006965.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1006965.g003</object-id><label>Fig 3</label><caption><title>DENV viremia and infectiousness trajectories by infection class.</title><p>(A,D,G,J): DENV viremia since time of infection for different infection classes and pre-exposure histories (1&#x000b0;: primary infection; 2&#x000b0;: secondary infection). Lighter lines denote 3,000 replicates and dark lines means. (B,E,H,K): Infectiousness of humans to mosquitoes over time. (C,F,I,L): Probability density of net infectiousness as defined in Eq (<xref ref-type="disp-formula" rid="ppat.1006965.e004">4</xref>) based on curves from the middle column. The solid blue line denotes the median and the dashed line denotes the median for the reference group (1&#x000b0; symptomatic). The solid and dashed red lines denote the mean and 95% confidence interval of the net infectiousness of 1&#x000b0; symptomatic infections as measured empirically [<xref rid="ppat.1006965.ref063" ref-type="bibr">63</xref>].</p></caption><graphic xlink:href="ppat.1006965.g003"/></fig></sec><sec id="sec005"><title>Relative contributions to force of infection (FoI)</title><p>Next, we estimated the proportion of each infection class in a hypothetical population and derived each class&#x02019; relative contribution to FoI, the rate at which susceptible people become infected. We assumed an equal probability of being bitten by <italic>Ae</italic>. <italic>aegypti</italic> across infection classes. To quantify the proportion of people with As, IS, UAS, and DAS infections (and thus the pool of individuals who could potentially give rise to new infections among susceptibles), we used estimates from a recent meta-analysis on published (As+IS):AS ratios for primary and secondary infections (1&#x000b0;: 82%, 95% CI: 81&#x02013;84; 2&#x000b0;: 76%, 95% CI: 74&#x02013;78) [<xref rid="ppat.1006965.ref023" ref-type="bibr">23</xref>]. Post-2&#x000b0; infections were assessed separately, using studies compiled by [<xref rid="ppat.1006965.ref007" ref-type="bibr">7</xref>]. A beta-binomial model of these proportions was supported over a binomial model (deviance information criterion (DIC) binomial: 163, beta-binomial: 34). We estimated the (As+IS):AS ratio among post-2&#x000b0; infections to be higher than that of 1&#x000b0; and 2&#x000b0; infections (86%, 95% CI: 63&#x02013;97). For all pre-exposure histories we adopted an As:(IS+AS) ratio of 9.2% (95% CI: 4.4&#x02013;14.0%), which reflects the proportion of asymptomatic infections detected among cluster participants in [<xref rid="ppat.1006965.ref016" ref-type="bibr">16</xref>] and a detection rate of AS infections of 8% (95% CI: 5&#x02013;15%) [<xref rid="ppat.1006965.ref024" ref-type="bibr">24</xref>] (see <xref ref-type="sec" rid="sec006">sensitivity analysis</xref> for an assessment of the full range of As:IS:AS ratios).</p><p>The proportion of individuals with a given pre-exposure history (e.g., no previous DENV exposure, prior exposure to one serotype), or with temporary heterotypic immunity or permanent homotypic immunity, depends on the age distribution and the history of local transmission intensity [<xref rid="ppat.1006965.ref025" ref-type="bibr">25</xref>]. We considered scenarios for our hypothetical populations with demographic characteristics of Brazil and Thailand, respectively, and simulated pre-exposure history by age across values of time-averaged FoI [<xref rid="ppat.1006965.ref026" ref-type="bibr">26</xref>] (Figs <xref ref-type="fig" rid="ppat.1006965.g004">4</xref> and <xref ref-type="supplementary-material" rid="ppat.1006965.s008">S2</xref>). Combining the aforementioned inapparent ratios with realistic demographic scenarios in a location with a given overall, time-averaged FoI, we derived formulas
<fig id="ppat.1006965.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1006965.g004</object-id><label>Fig 4</label><caption><title>Pre-exposure history (A and C) and infection class (B and D) stratification by age and for FoI values of 0.01 (top) and 0.1 (bottom).</title><p>An individuals&#x02019; susceptibility to infection and clinical outcome depend on pre-exposure history. Serohistory by age (A and C) is estimated using a system of ordinary differential equations with state variables denoting the proportion of the population pre-exposed to 0&#x02013;4 serotypes. Transition to pre-exposure state <italic>i</italic> occurs at rate <italic>i</italic>FoI. Individuals entering a new pre-exposure state have temporary heterologous immunity (gray) to all serotypes before later becoming susceptible again to each serotype to which they do not have a history of exposure. After four infections with four different serotypes, individuals are assumed fully immune (black) to all serotypes.</p></caption><graphic xlink:href="ppat.1006965.g004"/></fig>
<disp-formula id="ppat.1006965.e001"><alternatives><graphic xlink:href="ppat.1006965.e001.jpg" id="ppat.1006965.e001g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M1"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:msub><mml:mtext>FoI</mml:mtext><mml:mrow><mml:mtext>As</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>b</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mfrac><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>p</mml:mi></mml:munderover><mml:mrow><mml:mi>N</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mtext>As</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi>&#x003c3;</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mtext>As</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:mrow><mml:mrow><mml:mfrac><mml:mi>g</mml:mi><mml:mi>a</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>p</mml:mi></mml:munderover><mml:mrow><mml:mi>N</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mtext>As</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi>&#x003c3;</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mtext>As</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:mrow></mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mi>g</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mtext>FoI</mml:mtext><mml:mrow><mml:mtext>As+IS+UAS+DAS</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>b</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mfrac><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>p</mml:mi></mml:munderover><mml:mrow><mml:mi>N</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mtext>As</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi>&#x003c3;</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mtext>As</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>p</mml:mi></mml:munderover><mml:mrow><mml:mi>N</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mtext>IS</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi>&#x003c3;</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mtext>IS</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>p</mml:mi></mml:munderover><mml:mrow><mml:mi>N</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mtext>UAS</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi>&#x003c3;</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mtext>UAS</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>p</mml:mi></mml:munderover><mml:mrow><mml:mi>N</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mtext>DAS</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi>&#x003c3;</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mtext>DAS</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow><mml:mrow><mml:mfrac><mml:mi>g</mml:mi><mml:mi>a</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>p</mml:mi></mml:munderover><mml:mrow><mml:mi>N</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mtext>As</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi>&#x003c3;</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mtext>As</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>p</mml:mi></mml:munderover><mml:mrow><mml:mi>N</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mtext>IS</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi>&#x003c3;</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mtext>IS</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>p</mml:mi></mml:munderover><mml:mrow><mml:mi>N</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mtext>UAS</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi>&#x003c3;</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mtext>UAS</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>p</mml:mi></mml:munderover><mml:mrow><mml:mi>N</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mtext>DAS</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi>&#x003c3;</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mtext>DAS</mml:mtext><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mi>g</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(1)</label></disp-formula>
for the FoI attributable to As infections that can be divided by the overall FoI as FoI<sub>As</sub> / FoI<sub>As+IS+UAS+DAS</sub> to quantify the proportional contribution to FoI from the As class. The same approach can be applied to derive the proportional contribution to FoI of any other infection class. The parameters in Eq (<xref ref-type="disp-formula" rid="ppat.1006965.e001">1</xref>) are defined in <xref ref-type="supplementary-material" rid="ppat.1006965.s003">S1 Table</xref> and account for different aspects of local dengue epidemiology and the aforementioned descriptions of differential net infectiousness and prevalence of As, IS, and AS infections with distinct pre-exposure histories (see <italic><xref ref-type="sec" rid="sec009">Materials and Methods</xref></italic> for additional details).</p><p>Based on our metric of relative FoI, we estimated that 88% (95% CI: 77&#x02013;92%) of human DENV infections are attributable to individuals that do not present with apparent symptoms at the time when they are bitten by a susceptible mosquito (i.e., As, IS, and pre-symptomatic AS) (Figs <xref ref-type="fig" rid="ppat.1006965.g005">5</xref> and <xref ref-type="supplementary-material" rid="ppat.1006965.s009">S3</xref> for Thailand). We estimated that As and IS infections could together be responsible for causing 84% (95% CI: 82&#x02013;86%) of all human DENV infections, reflecting a near one-to-one relationship with their representation in the population. Of the remaining 16% (95% CI: 14&#x02013;18%) of infections, 76% (95% CI: 21&#x02013;100%) are attributable to bites by mosquitoes on people whose infection eventually becomes apparent, and thus potentially detectable, after onset of symptoms. At a detection rate of 8% [<xref rid="ppat.1006965.ref024" ref-type="bibr">24</xref>], an estimated 1.3% (95% CI: 1.1&#x02013;1.4%) of total infections result from infected individuals after they are detected by surveillance systems (0.8%, 95% CI: 0.7&#x02013;0.9%; 2.5%, 95% CI: 2.1&#x02013;2.7% at detection rates of 5% and 15% [<xref rid="ppat.1006965.ref024" ref-type="bibr">24</xref>], respectively).</p><fig id="ppat.1006965.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1006965.g005</object-id><label>Fig 5</label><caption><title>Mean contribution of each infection class to total force of infection (FoI).</title><p>The contribution to the total FoI of an infection class is derived from the ratio of FoI attributable to a given class and total FoI, as in Eq (<xref ref-type="disp-formula" rid="ppat.1006965.e001">1</xref>). The respective net infectiousness is derived from the 3,000 random samples displayed in <xref ref-type="fig" rid="ppat.1006965.g003">Fig 3</xref>. The infections are further distributed according to the estimated proportion of net infectiousness to occur before and after symptom onset (pre-symptomatic (Eq (<xref ref-type="disp-formula" rid="ppat.1006965.e005">5</xref>)) and post-symptomatic (hatched lines) (Eq (<xref ref-type="disp-formula" rid="ppat.1006965.e006">6</xref>)). The histogram shows the distribution of FoI contributions by asymptomatic infections at FoI = 0.1, accounting for parameter uncertainty.</p></caption><graphic xlink:href="ppat.1006965.g005"/></fig></sec><sec id="sec006"><title>Sensitivity analysis</title><p>Data on viremia and infectiousness in asymptomatic, pre-symptomatic, and post-2&#x000b0; infections are sparse [<xref rid="ppat.1006965.ref016" ref-type="bibr">16</xref>], resulting in substantial uncertainty around our estimates. We performed a variance-based sensitivity analysis [<xref rid="ppat.1006965.ref027" ref-type="bibr">27</xref>] to identify the primary sources of uncertainty for estimating net infectiousness and the proportion of net infectiousness occurring prior to symptom onset. Limited data on the viremia-to-infectiousness relationship of asymptomatic infections drove the majority of uncertainty in estimates of their net infectiousness, whereas uncertainty in time until symptom onset was responsible for the majority of uncertainty in estimates of the proportion of net infectiousness prior to symptom onset (<xref ref-type="supplementary-material" rid="ppat.1006965.s010">S4 Fig</xref>).</p><p>The estimated contributions to FoI by each infection class were robust across different transmission settings (<xref ref-type="fig" rid="ppat.1006965.g005">Fig 5</xref>) and in settings where DENV is newly emerging (<xref ref-type="supplementary-material" rid="ppat.1006965.s011">S5 Fig</xref>), but not when allowing for contributions to transmission from post-2&#x000b0; infections (<xref ref-type="supplementary-material" rid="ppat.1006965.s007">S1 Fig</xref>). Under the assumption that the net infectiousness of post-2&#x000b0; infections is equivalent to that of 2&#x000b0; infections, we estimated the contribution of inapparent infections to be up to 11% (95% CI: 10&#x02013;13%) higher than if post-2&#x000b0; infections had not been assumed to contribute to transmission (<xref ref-type="supplementary-material" rid="ppat.1006965.s007">S1 Fig</xref>). This increase resulted from the relatively high proportion of IS infections among post-2&#x000b0; infections, who made up a larger proportion of the infectious reservoir in more intense transmission settings. Under the assumption that IS infections are more similar in their infectiousness to As than to AS infections, the estimated contribution of inapparent infections was reduced from 84% to 73% (95% CI: 0&#x02013;91%), reflecting a lower bound on this assumption. The impact of accounting for the differential viral trajectories of severe dengue cases [<xref rid="ppat.1006965.ref018" ref-type="bibr">18</xref>] was minor due to their small numerical prominence [<xref rid="ppat.1006965.ref028" ref-type="bibr">28</xref>], but their inclusion did increase the contribution of post-symptomatic DAS infections from 1.0% (95% CI: 0.8&#x02013;1.1%) to 2.1% (95% CI: 0.8&#x02013;3.6).</p><p>As:IS:UAS:DAS ratios can fluctuate in space and time; for instance, as a result of serotype differences in virulence [<xref rid="ppat.1006965.ref007" ref-type="bibr">7</xref>,<xref rid="ppat.1006965.ref023" ref-type="bibr">23</xref>]. The contribution of inapparent (As+IS) infections across the spectrum of As:IS:AS ratios is driven by the ratio of As to IS infections, with the total contribution of As+IS infections generally being similar to their numerical prominence in the infected population (<xref ref-type="fig" rid="ppat.1006965.g006">Fig 6</xref>). Although variability in As:IS:AS ratios likely does drive some variability in the contribution of As+IS infections, our analysis suggests that their contribution is unlikely to be less than 81% of their numerical prominence (<xref ref-type="fig" rid="ppat.1006965.g006">Fig 6</xref>).</p><fig id="ppat.1006965.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1006965.g006</object-id><label>Fig 6</label><caption><title>Contribution to the total force of infection (FoI) of inapparent infections (As+IS) for different As:IS:AS ratios (FoI = 0.05).</title><p>Darker blue colors indicate a larger contribution to the FoI by As+IS infections in the population. The coordinates reflect the proportions per infection class with (0.09, 0.64,0.27) reflecting a default based on [<xref rid="ppat.1006965.ref016" ref-type="bibr">16</xref>]. The white lines indicate the expected proportion of inapparent contribution if all types of infections had an equal net infectiousness.</p></caption><graphic xlink:href="ppat.1006965.g006"/></fig></sec></sec><sec sec-type="conclusions" id="sec007"><title>Discussion</title><p>Combined with recent empirical findings [<xref rid="ppat.1006965.ref016" ref-type="bibr">16</xref>,<xref rid="ppat.1006965.ref018" ref-type="bibr">18</xref>], our modeling analysis suggests that inapparent infections contribute appreciably to DENV transmission and its disease burden via infection of others who develop clinical symptoms. In large part, our results stem from the large numerical prominence of As and IS DENV infections and the finding that differences in the viremia profiles of As and S infections are insufficient to result in considerable differences in net infectiousness. Moreover, our finding that approximately one quarter of an individual&#x02019;s infectiousness occurs prior to symptom onset supports the hypothesis that a large proportion of human-to-mosquito transmission is silent; i.e., it happens when there is no detectable illness [<xref rid="ppat.1006965.ref015" ref-type="bibr">15</xref>,<xref rid="ppat.1006965.ref016" ref-type="bibr">16</xref>].</p><p>The substantial role that inapparent infections play during dengue epidemics may result in more rapid transmission and geographic spread [<xref rid="ppat.1006965.ref003" ref-type="bibr">3</xref>] and, as a result, more widespread transmission prior to case-driven outbreak detection and onset of control efforts [<xref rid="ppat.1006965.ref029" ref-type="bibr">29</xref>]. The considerable potential for pre-symptomatic transmission further impedes the use of case data to predict whether an outbreak will occur and, if it does, what its final size will be [<xref rid="ppat.1006965.ref030" ref-type="bibr">30</xref>]. Despite increasing recognition of the importance of silent transmission to the epidemiology of a variety of pathogens, it is rarely taken into account in dengue models [<xref rid="ppat.1006965.ref031" ref-type="bibr">31</xref>&#x02013;<xref rid="ppat.1006965.ref034" ref-type="bibr">34</xref>].</p><p>Our results also highlight the potential significance of a key uncertainty in projections of the population-level impact of the recently licensed Dengvaxia vaccine, which is thought to protect some vaccine recipients against apparent disease but not infection [<xref rid="ppat.1006965.ref035" ref-type="bibr">35</xref>]. Although spared from disease, our results imply that breakthrough infections in these individuals could appreciably contribute to transmission and, therefore, limit the indirect effects of vaccination [<xref rid="ppat.1006965.ref031" ref-type="bibr">31</xref>,<xref rid="ppat.1006965.ref036" ref-type="bibr">36</xref>]. If individuals with asymptomatic or inapparent infections are as infectious as their apparent symptomatic counterparts, positive indirect effects of vaccine implementation in highly endemic settings would be reduced [<xref rid="ppat.1006965.ref031" ref-type="bibr">31</xref>,<xref rid="ppat.1006965.ref032" ref-type="bibr">32</xref>]. Conversely, adverse effects of vaccination in low-transmission settings, due to higher rates of severe disease in DENV-na&#x000ef;ve vaccine recipients [<xref rid="ppat.1006965.ref037" ref-type="bibr">37</xref>], would be offset to some degree if inapparent infections are important contributors to transmission given that this would increase the projected indirect effects of vaccination in those settings [<xref rid="ppat.1006965.ref031" ref-type="bibr">31</xref>,<xref rid="ppat.1006965.ref032" ref-type="bibr">32</xref>].</p><p>The contribution of silent infections to transmission helps explain the difficulty of carrying out control efforts in response to reported cases, particularly in intense transmission settings [<xref rid="ppat.1006965.ref029" ref-type="bibr">29</xref>]. That approach could be further impeded by substantial inter-individual variability in pre-symptomatic and asymptomatic infectiousness [<xref rid="ppat.1006965.ref029" ref-type="bibr">29</xref>]. If some people with silent infections are substantially more infectious than those with apparent infections, a significant portion of DENV transmission clusters would not be detected or contained by traditional surveillance efforts. Additional data are required to determine to what extent the observed variability in infectiousness results from uncertainty in the data or variability among individuals [<xref rid="ppat.1006965.ref033" ref-type="bibr">33</xref>,<xref rid="ppat.1006965.ref038" ref-type="bibr">38</xref>]. Improving strategies with enhanced potential to prevent infections, silent or otherwise, requires a deeper understanding of the spatial and temporal scales of transmission [<xref rid="ppat.1006965.ref039" ref-type="bibr">39</xref>].</p><p>Our results underscore the need to resolve substantial uncertainties about within-host DENV dynamics, in particular with respect to viremia and infectiousness of asymptomatic, pre-symptomatic, and post-2&#x000b0; infections. An improved understanding of differences in viremia profiles between 1&#x000b0; and 2&#x000b0; infections, and the mechanisms underlying those processes requires more detailed immunological and viremia titer data, including quantifications of infectious particles, particularly from earlier stages of the infection [<xref rid="ppat.1006965.ref038" ref-type="bibr">38</xref>,<xref rid="ppat.1006965.ref040" ref-type="bibr">40</xref>]. Similarly, a greater understanding of the factors underlying differences in viral trajectories [<xref rid="ppat.1006965.ref038" ref-type="bibr">38</xref>,<xref rid="ppat.1006965.ref041" ref-type="bibr">41</xref>,<xref rid="ppat.1006965.ref042" ref-type="bibr">42</xref>], infectiousness [<xref rid="ppat.1006965.ref041" ref-type="bibr">41</xref>&#x02013;<xref rid="ppat.1006965.ref043" ref-type="bibr">43</xref>], and disease rates [<xref rid="ppat.1006965.ref023" ref-type="bibr">23</xref>] between serotypes is needed to gain better, more context-specific estimates of the contributions of silent transmission to DENV transmission. Further, uncertainty about the net infectiousness of post-2&#x000b0; infections limits understanding of dengue dynamics overall [<xref rid="ppat.1006965.ref044" ref-type="bibr">44</xref>] and the contribution of silent transmission in particular. Acquiring this kind of empirical data is complicated by the difficulty of identifying people in these classes when they are viremic and the absence of diagnostic tools that reliably distinguish 2&#x000b0; from post-2&#x000b0; infections [<xref rid="ppat.1006965.ref045" ref-type="bibr">45</xref>]. Moreover, people with symptomatic infections may experience impaired mobility [<xref rid="ppat.1006965.ref046" ref-type="bibr">46</xref>] or otherwise modified interactions with mosquitoes, the impacts of which on net transmission are presently not well understood. Resolving these uncertainties and identifying effective strategies for mitigating the contributions of all infections, apparent or not, to DENV transmission will require comprehensive studies that combine field work and modeling to address the coupled nature of multiple transmission heterogeneities [<xref rid="ppat.1006965.ref033" ref-type="bibr">33</xref>] (see <xref ref-type="supplementary-material" rid="ppat.1006965.s001">S1 Text</xref> for a comprehensive discussion of additional limitations and research needs).</p></sec><sec sec-type="conclusions" id="sec008"><title>Conclusion</title><p>Heterogeneous infectiousness coupled with heterogeneity in disease symptoms is common across a wide range of pathogens [<xref rid="ppat.1006965.ref047" ref-type="bibr">47</xref>]. A more thorough, quantitative understanding of the factors underlying these heterogeneities and their role in pathogen transmission is critical for a more complete understanding of pathogen dynamics and, in turn, enhanced disease prevention [<xref rid="ppat.1006965.ref048" ref-type="bibr">48</xref>]. Our results advance understanding of these heterogeneities for dengue, showing that they are significant at both individual and population levels. In particular, our findings suggest that failing to acknowledge these coupled heterogeneities may significantly handicap understanding of DENV transmission dynamics, the effectiveness of dengue outbreak response efforts, and the evaluation of novel interventions for dengue prevention and control. These results show that additional emphasis on model-based approaches that bridge individual-level infection and population-level transmission processes have the potential to provide valuable insights for infectious disease prevention and control and for the identification of high-priority needs for future data collection.</p></sec><sec sec-type="materials|methods" id="sec009"><title>Materials and methods</title><sec id="sec010"><title>Class-specific viremia dynamics</title><p>We modeled viremia trajectories (log<sub>10</sub> cDNA copies/mL of plasma) using a model [<xref rid="ppat.1006965.ref018" ref-type="bibr">18</xref>] of virus and immune dynamics with four state variables&#x02014;uninfected target cells (<italic>x</italic>), infected targets cells (<italic>y</italic>), free viral particles (<italic>v</italic>), and a clearing immune response (<italic>z</italic>)&#x02014;according to
<disp-formula id="ppat.1006965.e002"><alternatives><graphic xlink:href="ppat.1006965.e002.jpg" id="ppat.1006965.e002g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M2"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>A</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003b3;</mml:mi><mml:mi>x</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mi>x</mml:mi><mml:mi>v</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>y</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mi>x</mml:mi><mml:mi>v</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003b4;</mml:mi><mml:mi>y</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mi>z</mml:mi><mml:mi>y</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>&#x003c9;</mml:mi><mml:mi>y</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003ba;</mml:mi><mml:mi>v</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>&#x003b7;</mml:mi><mml:mi>y</mml:mi><mml:mi>z</mml:mi><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(2)</label></disp-formula></p><p>The parameter <italic>A</italic> denotes the daily production rate of target cells, which die at rate &#x003b3; and become infected proportional to the concentration of free viral particles at rate &#x003b2;, assuming random mixing. Infected cells die at rate &#x003b4; and are cleared of infection at a rate proportional to the size of the immune response and the removal rate &#x003b1;. Free viral particles are produced by infected cells at rate &#x003c9; and are cleared at rate &#x003ba;. The immune response grows proportional to the number of infected cells at rate &#x003b7;. This model was fitted to individual plasma viral titers from primary (1&#x000b0;) and secondary (2&#x000b0;) apparent symptomatic (AS) DENV-1 infections [<xref rid="ppat.1006965.ref021" ref-type="bibr">21</xref>] using Markov chain Monte Carlo methods [<xref rid="ppat.1006965.ref018" ref-type="bibr">18</xref>]. We used <italic>n</italic> = 3,000 random samples from the joint posteriors from that analysis to model viremia trajectories for 1&#x000b0; and 2&#x000b0; AS infections. Inapparent symptomatic (IS) infections are assumed to have similar viremia as AS infections. To adapt this approach to model viremia trajectories of As infections, we relied on the observation by Duong et al. [<xref rid="ppat.1006965.ref016" ref-type="bibr">16</xref>] that log<sub>10</sub> viral titers of As infections were lower on average than those of S infections (76%, CI: 63&#x02013;88%). To account for uncertainty in this relationship, we took the ratio of 3,000 random samples from the normal distributions of symptomatic (mean: 6.27 +/- SE 0.14 log<sub>10</sub> cDNA copies/mL) and asymptomatic observed viremia (mean: 4.75 +/- SE 0.39 log<sub>10</sub> cDNA copies/mL) and reduced each viremia trajectories of AS infections by a random draw from the distribution of fractions to approximate the trajectories of As infections. In doing so, we assumed the duration of viremia to be similar in As and S infections on the basis of limited data from the study performed by Duong et al. [<xref rid="ppat.1006965.ref016" ref-type="bibr">16</xref>], which revealed no detectable differences in the duration of viremia between A and S infections.</p></sec><sec id="sec011"><title>Class-specific viremia-infectiousness relationships</title><p>To describe the probability of infecting a mosquito given an individual&#x02019;s viremia (<italic>V</italic>), we used logistic regression models
<disp-formula id="ppat.1006965.e003"><alternatives><graphic xlink:href="ppat.1006965.e003.jpg" id="ppat.1006965.e003g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M3"><mml:mrow><mml:mi>F</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>V</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mi>V</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(3)</label></disp-formula>
where &#x003b2;<sub>0</sub> and &#x003b2;<sub>1</sub> denote the logistic intercept and the slope coefficient for plasma viremia (log<sub>10</sub> cDNA copies per mL), respectively [<xref rid="ppat.1006965.ref049" ref-type="bibr">49</xref>] (see <xref ref-type="supplementary-material" rid="ppat.1006965.s002">S2 Text</xref> for fits to alternative functional forms). We fitted this relationship to data from DENV-infected symptomatic and asymptomatic individuals (<xref ref-type="supplementary-material" rid="ppat.1006965.s006">S4 Table</xref>) and found these relationships to be significantly different across infection classes (i.e., asymptomatic, pre-symptomatic, and post-symptomatic) but not with respect to serotype or pre-exposure history (i.e., primary vs. post-primary infection) [<xref rid="ppat.1006965.ref016" ref-type="bibr">16</xref>] (See <xref ref-type="supplementary-material" rid="ppat.1006965.s002">S2 Text</xref> for a formal comparison with other studies on DENV infectiousness [<xref rid="ppat.1006965.ref041" ref-type="bibr">41</xref>,<xref rid="ppat.1006965.ref042" ref-type="bibr">42</xref>]). Pre-symptomatic individuals become symptomatic after their intrinsic incubation period (IIP) is over, at which time they become subject to a significantly different relationship between viremia and infectiousness (<xref ref-type="supplementary-material" rid="ppat.1006965.s003">S1 Table</xref>). Each of 3,000 samples of symptomatic viremia trajectories had a corresponding duration of the IIP as informed by the posterior distributions derived in [<xref rid="ppat.1006965.ref018" ref-type="bibr">18</xref>]. These were paired within a given realization of the regression model with coefficients randomly drawn from the multivariate normal distribution of best fit parameters (<xref ref-type="supplementary-material" rid="ppat.1006965.s003">S1 Table</xref>), so as to explicitly account for uncertainty in these estimates resulting from limited sample sizes in this study, in particular for As infections [<xref rid="ppat.1006965.ref016" ref-type="bibr">16</xref>]. The pre-symptomatic parameterization was used before the IIP concludes, and the post-symptomatic parameterization was used afterwards. For the infectiousness of asymptomatic infections, the viremia-infectiousness relationship remained the same over the course of the infection, because the concepts of IIP and onset of symptoms do not apply to asymptomatic infections. To summarize the extent of infectiousness of an individual over the entire course of their infection, we defined net infectiousness as the integral of an infectiousness curve over time
<disp-formula id="ppat.1006965.e004"><alternatives><graphic xlink:href="ppat.1006965.e004.jpg" id="ppat.1006965.e004g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M4"><mml:mrow><mml:mi>N</mml:mi><mml:mi>I</mml:mi><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:mrow><mml:mo>&#x0222b;</mml:mo><mml:mrow><mml:mi>F</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>V</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives><label>(4)</label></disp-formula></p><p>This quantity <italic>NI</italic> is proportional to the expected number of mosquitoes infected by a human infection assuming that biting occurs at a constant rate over the course of the human infection. By extension, the ratio of the net infectiousness of two individuals with two different types of infections is identical to the ratio of the expected number of mosquitoes infected by people with those respective types of infections. Given that we interpret the end of the intrinsic incubation period (IIP) as the beginning of the symptomatic phase of the infection, we also used this distinction to estimate the proportion of infectiousness that occurs prior to symptom onset (NI<sub>PreS</sub>)
<disp-formula id="ppat.1006965.e005"><alternatives><graphic xlink:href="ppat.1006965.e005.jpg" id="ppat.1006965.e005g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M5"><mml:mrow><mml:mi>N</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>&#x0222b;</mml:mo><mml:mn>0</mml:mn><mml:mrow><mml:mi>I</mml:mi><mml:mi>I</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:mi>F</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>V</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(5)</label></disp-formula>
and likewise for the proportion after symptom onset
<disp-formula id="ppat.1006965.e006"><alternatives><graphic xlink:href="ppat.1006965.e006.jpg" id="ppat.1006965.e006g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M6"><mml:mrow><mml:mi>N</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>P</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>&#x0222b;</mml:mo><mml:mrow><mml:mi>I</mml:mi><mml:mi>I</mml:mi><mml:mi>P</mml:mi></mml:mrow><mml:mi>&#x0221e;</mml:mi></mml:munderover><mml:mrow><mml:mi>F</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>V</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:math></alternatives><label>(6)</label></disp-formula></p></sec><sec id="sec012"><title>Proportion of 1&#x000b0;, 2&#x000b0;, and post-2&#x000b0; infections as a function of transmission intensity</title><p>We calculated the proportion of the population previously exposed to 0 to 4 serotypes as a function of the population&#x02019;s age distribution and the time-averaged, serotype-specific FoI to which the population is subject. The time-averaged FoI metric (defined below) that we used was assumed to be constant with respect to virus serotype and space. Although DENV FoI is known to exhibit substantial variation with respect to these factors [<xref rid="ppat.1006965.ref026" ref-type="bibr">26</xref>,<xref rid="ppat.1006965.ref050" ref-type="bibr">50</xref>], we simplified this aspect of our analysis to reflect the average across a wide geographic area or across many realizations of a complex temporal pattern of transmission.</p><p>Consistent with these assumptions and with the further assumption of FoI acting as a constant hazard, we represented the proportion pre-exposed to <italic>i</italic> = 0&#x02026;4 serotypes at age <italic>a</italic> as <italic>e</italic><sub><italic>i</italic></sub>(<italic>a</italic>). After acquiring infection at rate (4-<italic>i</italic>)FoI, an individual has temporary heterologous immunity to all serotypes for a period of average duration &#x003c3;<sup>-1</sup>. The probability that an individual of age <italic>a</italic> has temporary heterologous immunity after exposure with <italic>i</italic> serotypes is represented by <italic>r</italic><sub><italic>i</italic></sub> (<italic>a</italic>). Individuals permanently retain immunity to serotypes to which they were previously exposed; i.e., permanent homologous immunity. The dynamics of these classes with respect to age follow
<disp-formula id="ppat.1006965.e007"><alternatives><graphic xlink:href="ppat.1006965.e007.jpg" id="ppat.1006965.e007g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M7"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>e</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>4</mml:mn><mml:mo>&#x000a0;</mml:mo><mml:mtext>FoI</mml:mtext><mml:mo>&#x000a0;</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>r</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:mfrac><mml:msub><mml:mo>|</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02026;</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>4</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x000a0;</mml:mo><mml:mtext>FoI</mml:mtext><mml:mo>&#x000a0;</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003c3;</mml:mi><mml:msub><mml:mi>r</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>e</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:mfrac><mml:msub><mml:mo>|</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02026;</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>&#x003c3;</mml:mi><mml:msub><mml:mi>r</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#x02212;</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>4</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x000a0;</mml:mo><mml:mtext>FoI</mml:mtext><mml:mo>&#x000a0;</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(7)</label></disp-formula></p><p>Accounting for the proportion of the population in each age group <italic>p</italic>(<italic>a</italic>), the population-wide proportion pre-exposed to <italic>i</italic> serotypes is
<disp-formula id="ppat.1006965.e008"><alternatives><graphic xlink:href="ppat.1006965.e008.jpg" id="ppat.1006965.e008g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M8"><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>&#x02211;</mml:mo><mml:mi>a</mml:mi></mml:munder><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:math></alternatives><label>(8)</label></disp-formula>
where <italic>p</italic>(<italic>a</italic>) was informed by national age distributions from Brazil and Thailand [<xref rid="ppat.1006965.ref051" ref-type="bibr">51</xref>], as representative examples of two DENV-endemic regions.</p></sec><sec id="sec013"><title>Proportion of infections of each class among 1&#x000b0;, 2&#x000b0;, and post-2&#x000b0; infections</title><p>As+IS:AS ratios for primary and secondary infections were derived from a recent meta-analysis using cohort studies with laboratory-confirmed infections [<xref rid="ppat.1006965.ref023" ref-type="bibr">23</xref>]. In brief, a literature search was performed for dengue cohort studies that 1) reported the number of (As+IS) and AS infections and 2) provided lab confirmation of apparent infections [<xref rid="ppat.1006965.ref022" ref-type="bibr">22</xref>,<xref rid="ppat.1006965.ref052" ref-type="bibr">52</xref>&#x02013;<xref rid="ppat.1006965.ref059" ref-type="bibr">59</xref>] (<xref ref-type="supplementary-material" rid="ppat.1006965.s005">S3 Table</xref>). For a specific time and place <italic>j</italic>, observed infections with pre-exposure to <italic>i</italic> serotypes (<italic>O</italic><sub><italic>i</italic></sub>) were assumed to result from a binomial distribution <inline-formula id="ppat.1006965.e009"><alternatives><graphic xlink:href="ppat.1006965.e009.jpg" id="ppat.1006965.e009g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M9"><mml:mrow><mml:msub><mml:mi>O</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>A</mml:mi><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x0223c;</mml:mo><mml:mi>B</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>&#x003b6;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>&#x003bb;</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> where <italic>N</italic><sub><italic>i</italic></sub> is the number of subjects pre-exposed to <italic>i</italic> serotypes, <inline-formula id="ppat.1006965.e010"><alternatives><graphic xlink:href="ppat.1006965.e010.jpg" id="ppat.1006965.e010g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M10"><mml:mi>&#x003b6;</mml:mi></mml:math></alternatives></inline-formula>the (As+IS):AS ratio, and &#x003bb; the location- and time-specific force of infection. Similarly, the observed AS infections were assumed to result from <inline-formula id="ppat.1006965.e011"><alternatives><graphic xlink:href="ppat.1006965.e011.jpg" id="ppat.1006965.e011g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M11"><mml:mrow><mml:msub><mml:mi>O</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>A</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x0223c;</mml:mo><mml:mi>B</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b6;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>&#x003bb;</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>The models were fit to the data in a Bayesian framework with the R package <italic>RStan</italic> [<xref rid="ppat.1006965.ref060" ref-type="bibr">60</xref>]. We assessed observations on post-2&#x000b0; infections [<xref rid="ppat.1006965.ref022" ref-type="bibr">22</xref>,<xref rid="ppat.1006965.ref028" ref-type="bibr">28</xref>], as collated by [<xref rid="ppat.1006965.ref007" ref-type="bibr">7</xref>] in a similar fashion and assumed the number of As+IS infections to have arisen from a binomial distribution <inline-formula id="ppat.1006965.e012"><alternatives><graphic xlink:href="ppat.1006965.e012.jpg" id="ppat.1006965.e012g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M12"><mml:mrow><mml:msub><mml:mi>O</mml:mi><mml:mrow><mml:mo>&#x02265;</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>A</mml:mi><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x0223c;</mml:mo><mml:mi>B</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>O</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>O</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>&#x003be;</mml:mi><mml:mrow><mml:mo>&#x02265;</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> To account for intrinsic variability in the rates, similar models assuming a beta-binomial distribution were assessed and compared to the binomial model using DIC [<xref rid="ppat.1006965.ref061" ref-type="bibr">61</xref>]. Given the scarcity of data and the fact that these estimates comprise only a portion of our analysis, we did not estimate &#x003bb;<sub>i</sub> as was done in [<xref rid="ppat.1006965.ref023" ref-type="bibr">23</xref>]. Had we done so, we would expect our estimates of that quantity to be similar.</p><p>To calculate the proportions of infected people who have previously been exposed to zero or one serotype and who experience either an asymptomatic (A) or symptomatic (S) infection, we used <italic>E</italic><sub><italic>i</italic></sub> and our estimates of As:S ratios for a given pre-exposure history (<inline-formula id="ppat.1006965.e013"><alternatives><graphic xlink:href="ppat.1006965.e013.jpg" id="ppat.1006965.e013g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M13"><mml:mrow><mml:msub><mml:mi>&#x003b8;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>= 9.2% for 1&#x000b0; and 2&#x000b0; infections, other options are assessed in <xref ref-type="fig" rid="ppat.1006965.g006">Fig 6</xref>), resulting in
<disp-formula id="ppat.1006965.e014"><alternatives><graphic xlink:href="ppat.1006965.e014.jpg" id="ppat.1006965.e014g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M14"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mi mathvariant="normal">Pr</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mtext>As</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:munderover><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mstyle><mml:msub><mml:mi>&#x003b8;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi mathvariant="normal">Pr</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mtext>S</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:munderover><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo></mml:mrow></mml:mstyle><mml:msub><mml:mi>&#x003b8;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(9)</label></disp-formula></p><p>Similarly, the proportion of infections found to be inapparent symptomatic (IS) or apparent symptomatic (AS) follows from the (As+IS):AS ratio, <inline-formula id="ppat.1006965.e015"><alternatives><graphic xlink:href="ppat.1006965.e015.jpg" id="ppat.1006965.e015g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M15"><mml:mi>&#x003b6;</mml:mi></mml:math></alternatives></inline-formula>, as
<disp-formula id="ppat.1006965.e016"><alternatives><graphic xlink:href="ppat.1006965.e016.jpg" id="ppat.1006965.e016g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M16"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mi mathvariant="normal">Pr</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mtext>As+IS</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:munderover><mml:mrow><mml:msub><mml:mi>&#x003b6;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>E</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi mathvariant="normal">Pr</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mtext>AS</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:munderover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b6;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi mathvariant="normal">Pr</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mtext>IS</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi mathvariant="normal">Pr</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mtext>As+IS</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mi mathvariant="normal">Pr</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mtext>As</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(10)</label></disp-formula></p></sec><sec id="sec014"><title>Theoretical formula for contribution of each infection class to force of infection</title><p>Classical epidemiological theory for mosquito-borne pathogen transmission posits that FoI&#x02014;i.e., the rate at which susceptible individuals become infected&#x02014;is a function of a number of factors, including infection prevalence among hosts (<italic>X</italic>) and the infectiousness of infected hosts [<xref rid="ppat.1006965.ref062" ref-type="bibr">62</xref>]. On a per capita basis, FoI = <italic>bmaY</italic> in Ross-Macdonald models, where <italic>b</italic> is the probability that a susceptible host becomes infected after being bitten by an infectious vector, <italic>m</italic> is the ratio of vectors to hosts, <italic>a</italic> is the daily rate of at which a vector bites, and <italic>Y</italic> is the infection prevalence among vectors. The latter depends further on the daily vector mortality rate <italic>g</italic>, the incubation period <italic>n</italic> in the vector, human infection prevalence <italic>X</italic>, and the probability <italic>c</italic> that a susceptible mosquito becomes infected upon biting an infectious host [<xref rid="ppat.1006965.ref062" ref-type="bibr">62</xref>].</p><p>To account for the population stratification that is necessary for our analysis, we derived a formula for the FoI that is more generalizable than the classic formula in that it allows for distinct contributions to FoI from different host groups (i.e., As, IS, UAS, and DAS infections with different pre-exposure histories). Specifically, each host group differed in its infectiousness and its overall prevalence in the population. By separating contributions from different host groups to mosquito infectiousness and, in turn, to the FoI on susceptible hosts, we calculated the proportional contribution of people with As infections to FoI by calculating the ratio between the FoI resulting from As infections alone and the total FoI, and similarly for IS, UAS, and DAS infections.</p><p>Differentiating between S and As infections, we can describe FoI as
<disp-formula id="ppat.1006965.e017"><alternatives><graphic xlink:href="ppat.1006965.e017.jpg" id="ppat.1006965.e017g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M17"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:msub><mml:mtext>FoI</mml:mtext><mml:mrow><mml:mtext>As</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>b</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mfrac><mml:mrow><mml:mi>a</mml:mi><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mtext>As</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mtext>As</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>g</mml:mi><mml:mo>+</mml:mo><mml:mi>a</mml:mi><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mtext>As</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mtext>As</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mi>g</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mtext>FoI</mml:mtext><mml:mrow><mml:mtext>S+As</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>b</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mfrac><mml:mrow><mml:mi>a</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mtext>As</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003c1;</mml:mi><mml:msub><mml:mi>c</mml:mi><mml:mtext>S</mml:mtext></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mtext>As</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>g</mml:mi><mml:mo>+</mml:mo><mml:mi>a</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mtext>As</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003c1;</mml:mi><mml:msub><mml:mi>c</mml:mi><mml:mtext>S</mml:mtext></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mtext>As</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mi>g</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives><label>(11)</label></disp-formula>
where &#x003c1; is the prevalence of S infections relative to As. The contribution of As infections follows from dividing the quantities in (11) as
<disp-formula id="ppat.1006965.e018"><alternatives><graphic xlink:href="ppat.1006965.e018.jpg" id="ppat.1006965.e018g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M18"><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mtext>FoI</mml:mtext></mml:mrow><mml:mrow><mml:mtext>As</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mtext>FoI</mml:mtext></mml:mrow><mml:mrow><mml:mtext>S+As</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>&#x003c1;</mml:mi><mml:msub><mml:mi>c</mml:mi><mml:mtext>S</mml:mtext></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mtext>As</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mrow><mml:mfrac><mml:mi>g</mml:mi><mml:mi>a</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mtext>As</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mtext>As</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mfrac><mml:mi>g</mml:mi><mml:mi>a</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mtext>As</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003c1;</mml:mi><mml:msub><mml:mi>c</mml:mi><mml:mtext>S</mml:mtext></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mtext>As</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(12)</label></disp-formula>
which demonstrates the robustness of our results to different values of <italic>n</italic>, <italic>b</italic>, and <italic>m</italic>.</p><p>Under a Ross-Macdonald formulation, the time-invariant infection probability <italic>c</italic> relates to net infectiousness (<italic>NI</italic>) according to <inline-formula id="ppat.1006965.e019"><alternatives><graphic xlink:href="ppat.1006965.e019.jpg" id="ppat.1006965.e019g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M19"><mml:mrow><mml:mspace width="0.25em"/><mml:mi>N</mml:mi><mml:mi>I</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mi>c</mml:mi><mml:mo>/</mml:mo><mml:mi>&#x003b9;</mml:mi></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>, where <inline-formula id="ppat.1006965.e020"><alternatives><graphic xlink:href="ppat.1006965.e020.jpg" id="ppat.1006965.e020g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M20"><mml:mrow><mml:msup><mml:mi>&#x003b9;</mml:mi><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></alternatives></inline-formula> represents the average duration of the period of infectiousness. The prevalence <italic>X</italic><sub><italic>i</italic></sub> is proportional to the proportion of the population that has temporary heterologous immunity, <italic>R</italic><sub><italic>i</italic></sub>, according to <inline-formula id="ppat.1006965.e021"><alternatives><graphic xlink:href="ppat.1006965.e021.jpg" id="ppat.1006965.e021g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M21"><mml:mrow><mml:msub><mml:mi mathvariant="italic">X</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mi>&#x003c3;</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mi>&#x003b9;</mml:mi></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>The quantity <italic>R</italic><sub><italic>i</italic></sub> is defined from Eq (<xref ref-type="disp-formula" rid="ppat.1006965.e007">7</xref>) according to <inline-formula id="ppat.1006965.e022"><alternatives><graphic xlink:href="ppat.1006965.e022.jpg" id="ppat.1006965.e022g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M22"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> It follows that
<disp-formula id="ppat.1006965.e023"><alternatives><graphic xlink:href="ppat.1006965.e023.jpg" id="ppat.1006965.e023g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M23"><mml:mrow><mml:mi>c</mml:mi><mml:msub><mml:mi>X</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>N</mml:mi><mml:mi>I</mml:mi><mml:mi>&#x003c3;</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math></alternatives><label>(13)</label></disp-formula></p><p>Substituting Eq (<xref ref-type="disp-formula" rid="ppat.1006965.e023">13</xref>) into Eq (<xref ref-type="disp-formula" rid="ppat.1006965.e017">11</xref>) to further stratify infection classes and pre-exposure histories gives Eq (<xref ref-type="disp-formula" rid="ppat.1006965.e001">1</xref>) from the Results section, with <italic>p</italic> = 2 when assessing the impact of 1&#x000b0; and 2&#x000b0; infections on transmission and <italic>p</italic> = 4 when assessing the impact of 1&#x000b0;, 2&#x000b0;, and post-2&#x000b0; infections on transmission. To account for uncertainty in this metric, the relative FoI was calculated for <italic>n</italic> = 3,000 random samples from the distributions of <italic>NI</italic> for each infection class.</p></sec><sec id="sec015"><title>Sensitivity analysis</title><p>We performed a sensitivity analysis to assess the impact of uncertainty in As:IS:AS ratios among 1&#x000b0; and 2&#x000b0; infections on the relative contributions to the overall FoI (<xref ref-type="fig" rid="ppat.1006965.g006">Fig 6</xref>). Additionally, we examined what the contribution of inapparent infections to the FoI would be under the assumption that post-2&#x000b0; infections are similarly infectious as 2&#x000b0; infections and using estimates from the meta-analysis presented in <xref ref-type="supplementary-material" rid="ppat.1006965.s005">S3 Table</xref> to estimate the proportion of post-2&#x000b0; infections to be apparent. This and the assumption we effectively made in our primary analysis&#x02014;i.e., that post-2&#x000b0; infections make no contribution to transmission&#x02014;represent two different extremes and therefore provide bounds on the potential sensitivity of our results to alternative assumptions about the contributions to transmission from post-2&#x000b0; infections. Similarly, we addressed uncertainty around the net infectiousness of IS infections by first assuming their net infectiousness to be similar to As infections rather than AS infections, as in the core analysis. We then examined the impact of severe AS infections by adopting fitted dengue hemorrhagic fever (DHF) viremia trajectories [<xref rid="ppat.1006965.ref018" ref-type="bibr">18</xref>], DHF rates among S infections of 0.8% and 3% for primary and post-primary infections, respectively [<xref rid="ppat.1006965.ref028" ref-type="bibr">28</xref>], and the assumption that all DHF cases are detected. The latter assumption provides an upper bound for the potential contribution of DAS infections for a given detection rate.</p></sec><sec id="sec016"><title>Variance-based sensitivity analysis</title><p>To assess the impact of the three main sources of uncertainty in deriving two outcome variables (<italic>Q</italic>), the net infectiousness and the proportion of infectiousness prior to symptoms, we performed a variance-based sensitivity analysis [<xref rid="ppat.1006965.ref027" ref-type="bibr">27</xref>]. The variance for both variables was measured under four different scenarios: 1) with all sources of uncertainty and 2&#x02013;4) with all sources of uncertainty except one. The contribution to the total variance is expressed by the total-effect index
<disp-formula id="ppat.1006965.e024"><alternatives><graphic xlink:href="ppat.1006965.e024.jpg" id="ppat.1006965.e024g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M24"><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mfrac><mml:mrow><mml:mi>V</mml:mi><mml:mi>a</mml:mi><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mo>~</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>Q</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>V</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>Q</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:math></alternatives><label>(14)</label></disp-formula>
Here, <bold>X</bold> denotes a vector of uncertain model inputs and ~<italic>i</italic> denotes that uncertainty around all inputs was included with the exclusion of <italic>i</italic>. For input <italic>i</italic>, we used the mean of the uncertainty distribution for the quantity of interest. The three main sources of uncertainty are quantities describing temporal patterns of viremia, the relationship between viremia and infectiousness, and the duration of the intrinsic incubation period (IIP).</p></sec></sec><sec sec-type="supplementary-material" id="sec017"><title>Supporting information</title><supplementary-material content-type="local-data" id="ppat.1006965.s001"><label>S1 Text</label><caption><title>Assessment of model assumptions and limitations.</title><p>(PDF)</p></caption><media xlink:href="ppat.1006965.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1006965.s002"><label>S2 Text</label><caption><title>Assessment of infectiousness data.</title><p>(PDF)</p></caption><media xlink:href="ppat.1006965.s002.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1006965.s003"><label>S1 Table</label><caption><title>Model parameters.</title><p>(PDF)</p></caption><media xlink:href="ppat.1006965.s003.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1006965.s004"><label>S2 Table</label><caption><title>Probabilistic comparison of net infectiousness uncertainty distributions.</title><p>(PDF)</p></caption><media xlink:href="ppat.1006965.s004.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1006965.s005"><label>S3 Table</label><caption><title>Cohort studies addressing (As+IS): AS ratios in primary (1&#x000b0;), secondary (2&#x000b0;) infections, and post-2&#x000b0; infections.</title><p>Studies for 1&#x000b0; and 2&#x000b0; were collated in [<xref rid="ppat.1006965.ref023" ref-type="bibr">23</xref>]. Studies used for post-2&#x000b0; [<xref rid="ppat.1006965.ref022" ref-type="bibr">22</xref>,<xref rid="ppat.1006965.ref028" ref-type="bibr">28</xref>] were derived from [<xref rid="ppat.1006965.ref007" ref-type="bibr">7</xref>]. N.S. = not stated.</p><p>(XLSX)</p></caption><media xlink:href="ppat.1006965.s005.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1006965.s006"><label>S4 Table</label><caption><title>Data from direct feeding experiment [<xref rid="ppat.1006965.ref016" ref-type="bibr">16</xref>] used to inform viremia to infectiousness relationship.</title><p>(XLSX)</p></caption><media xlink:href="ppat.1006965.s006.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1006965.s007"><label>S1 Fig</label><caption><title>Mean contribution of infection classes to total force of infection (FoI) when accounting for the contribution of post-secondary infections to transmission.</title><p>The contribution to the total FoI of a class is derived from the ratio between FoI attributable to this class and total FoI, as in Eq (<xref ref-type="disp-formula" rid="ppat.1006965.e001">1</xref>). The respective net infectiousness is derived from the 3,000 random samples displayed in <xref ref-type="fig" rid="ppat.1006965.g003">Fig 3</xref>. The infections are further distributed according to the estimated proportion of net infectiousness to occur before and after symptom onset (pre-symptomatic (Eq (<xref ref-type="disp-formula" rid="ppat.1006965.e005">5</xref>)) and post-symptomatic (hatched lines) (Eq (<xref ref-type="disp-formula" rid="ppat.1006965.e006">6</xref>)). The histogram shows the distribution of FoI contributions by asymptomatic infections at FoI = 0.1, accounting for parameter uncertainty. Post-secondary infections are assumed to follow the same viremia trajectory as secondary infections. 86% of post-secondary infections are As or IS (<xref ref-type="supplementary-material" rid="ppat.1006965.s005">S3 Table</xref>).</p><p>(PDF)</p></caption><media xlink:href="ppat.1006965.s007.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1006965.s008"><label>S2 Fig</label><caption><title>Pre-exposure profile as a function of the force of infection for (a) Brazil, (b) Thailand.</title><p>The seroprevalence of the population is estimated using a system of ordinary differential equations with state variables denoting the proportion of the population pre-exposed to 0&#x02013;4 serotypes. Transition to pre-exposure state i occurs at a rate (4-i)FoI. Individuals entering a new pre-exposure state retain temporary heterologous immunity to all serotypes for an average duration of 2 years [<xref rid="ppat.1006965.ref064" ref-type="bibr">64</xref>] before becoming susceptible to heterologous serotypes.</p><p>(PDF)</p></caption><media xlink:href="ppat.1006965.s008.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1006965.s009"><label>S3 Fig</label><caption><title>Mean contribution of infection classes to total force of infection (FoI) for Thailand.</title><p>The contribution to the total FoI of a class is derived from the ratio between FoI attributable to this class and total FoI, as in Eq (<xref ref-type="disp-formula" rid="ppat.1006965.e001">1</xref>). The respective net infectiousness is derived from the 3,000 random samples displayed in <xref ref-type="fig" rid="ppat.1006965.g003">Fig 3</xref>. The infections are further distributed according to the estimated proportion of net infectiousness to occur before and after symptom onset (pre-symptomatic (Eq (<xref ref-type="disp-formula" rid="ppat.1006965.e005">5</xref>)) and post-symptomatic (hatched lines) (Eq (<xref ref-type="disp-formula" rid="ppat.1006965.e006">6</xref>)). The histogram shows the distribution of FoI contributions by asymptomatic infections at FoI = 0.1, accounting for parameter uncertainty.</p><p>(PDF)</p></caption><media xlink:href="ppat.1006965.s009.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1006965.s010"><label>S4 Fig</label><caption><title>Variance-based sensitivity analysis.</title><p>The contribution to the variance represents the total effect index, denoting the contribution of each source of uncertainty to the total variance, including its interactions. (IIP = intrinsic incubation period).</p><p>(PDF)</p></caption><media xlink:href="ppat.1006965.s010.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="ppat.1006965.s011"><label>S5 Fig</label><caption><title>Mean contribution of infection classes to total FoI in an emerging setting.</title><p>The contribution to the total FoI of a class is derived from the ratio between FoI attributable to this class and total FoI, as in Eq (<xref ref-type="disp-formula" rid="ppat.1006965.e001">1</xref>). The respective net infectiousness is derived from the 3,000 random samples displayed in <xref ref-type="fig" rid="ppat.1006965.g003">Fig 3</xref>. The infections are further distributed according to the estimated proportion of net infectiousness to occur before and after symptom onset (pre-symptomatic (Eq (<xref ref-type="disp-formula" rid="ppat.1006965.e005">5</xref>)) and post-symptomatic (hatched lines) (Eq (<xref ref-type="disp-formula" rid="ppat.1006965.e006">6</xref>)). The histogram shows the distribution of FoI contributions by asymptomatic infections at FoI = 0.1, accounting for parameter uncertainty.</p><p>(PDF)</p></caption><media xlink:href="ppat.1006965.s011.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank Cameron Simmons for facilitating access to data on viremia-infectiousness relationships for our analysis.</p></ack><ref-list><title>References</title><ref id="ppat.1006965.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Stone</surname><given-names>W</given-names></name>, <name><surname>Gon&#x000e7;alves</surname><given-names>BP</given-names></name>, <name><surname>Bousema</surname><given-names>T</given-names></name>, <name><surname>Drakeley</surname><given-names>C</given-names></name>. <article-title>Assessing the infectious reservoir of falciparum malaria: past and future</article-title>. <source>Trends Parasitol</source>. <year>2015</year>;<volume>31</volume>: <fpage>287</fpage>&#x02013;<lpage>296</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.pt.2015.04.004">10.1016/j.pt.2015.04.004</ext-link></comment>
<?supplied-pmid 25985898?><pub-id pub-id-type="pmid">25985898</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Althouse</surname><given-names>BM</given-names></name>, <name><surname>Scarpino</surname><given-names>SV</given-names></name>. <article-title>Asymptomatic transmission and the resurgence of Bordetella pertussis</article-title>. <source>BMC Med</source>. <year>2015</year>;<volume>13</volume>: <fpage>146</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12916-015-0382-8">10.1186/s12916-015-0382-8</ext-link></comment>
<?supplied-pmid 26103968?><pub-id pub-id-type="pmid">26103968</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>King</surname><given-names>AA</given-names></name>, <name><surname>Ionides</surname><given-names>EL</given-names></name>, <name><surname>Pascual</surname><given-names>M</given-names></name>, <name><surname>Bouma</surname><given-names>MJ</given-names></name>. <article-title>Inapparent infections and cholera dynamics</article-title>. <source>Nature</source>. <year>2008</year>;<volume>454</volume>: <fpage>877</fpage>&#x02013;<lpage>880</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature07084">10.1038/nature07084</ext-link></comment>
<?supplied-pmid 18704085?><pub-id pub-id-type="pmid">18704085</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>I</given-names></name>, <name><surname>Clarke</surname><given-names>SE</given-names></name>, <name><surname>Gosling</surname><given-names>R</given-names></name>, <name><surname>Hamainza</surname><given-names>B</given-names></name>, <name><surname>Killeen</surname><given-names>G</given-names></name>, <name><surname>Magill</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>"Asymptomatic" Malaria: A Chronic and Debilitating Infection That Should Be Treated</article-title>. <source>PLoS Med</source>. <year>2016</year>;<volume>13</volume>: <fpage>e1001942</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pmed.1001942">10.1371/journal.pmed.1001942</ext-link></comment>
<?supplied-pmid 26783752?><pub-id pub-id-type="pmid">26783752</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Johansson</surname><given-names>MA</given-names></name>, <name><surname>Vasconcelos</surname><given-names>PF</given-names></name>, <name><surname>Staples</surname><given-names>JE</given-names></name>. <article-title>The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases</article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>2014</year>;<volume>108</volume>: <fpage>482</fpage>&#x02013;<lpage>487</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/trstmh/tru092">10.1093/trstmh/tru092</ext-link></comment>
<?supplied-pmid 24980556?><pub-id pub-id-type="pmid">24980556</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Pitzer</surname><given-names>VE</given-names></name>, <name><surname>Bowles</surname><given-names>CC</given-names></name>, <name><surname>Baker</surname><given-names>S</given-names></name>, <name><surname>Kang</surname><given-names>G</given-names></name>, <name><surname>Balaji</surname><given-names>V</given-names></name>, <name><surname>Farrar</surname><given-names>JJ</given-names></name>, <etal>et al</etal>
<article-title>Predicting the impact of vaccination on the transmission dynamics of typhoid in South Asia: a mathematical modeling study</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2014</year>;<volume>8</volume>: <fpage>e2642</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0002642">10.1371/journal.pntd.0002642</ext-link></comment>
<?supplied-pmid 24416466?><pub-id pub-id-type="pmid">24416466</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Grange</surname><given-names>L</given-names></name>, <name><surname>Simon-Loriere</surname><given-names>E</given-names></name>, <name><surname>Sakuntabhai</surname><given-names>A</given-names></name>, <name><surname>Gresh</surname><given-names>L</given-names></name>, <name><surname>Paul</surname><given-names>R</given-names></name>, <name><surname>Harris</surname><given-names>E</given-names></name>. <article-title>Epidemiological risk factors associated with high global frequency of inapparent dengue virus infections</article-title>. <source>Frontiers in immunology</source>. <year>2014</year>;<volume>5</volume>.</mixed-citation></ref><ref id="ppat.1006965.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Bhatt</surname><given-names>S</given-names></name>, <name><surname>Gething</surname><given-names>PW</given-names></name>, <name><surname>Brady</surname><given-names>OJ</given-names></name>, <name><surname>Messina</surname><given-names>JP</given-names></name>, <name><surname>Farlow</surname><given-names>AW</given-names></name>, <name><surname>Moyes</surname><given-names>CL</given-names></name>, <etal>et al</etal>
<article-title>The global distribution and burden of dengue</article-title>. <source>Nature</source>. <year>2013</year>;<volume>496</volume>: <fpage>504</fpage>&#x02013;<lpage>507</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature12060">10.1038/nature12060</ext-link></comment>
<?supplied-pmid 23563266?><pub-id pub-id-type="pmid">23563266</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Lambrechts</surname><given-names>L</given-names></name>, <name><surname>Scott</surname><given-names>TW</given-names></name>, <name><surname>Gubler</surname><given-names>DJ</given-names></name>. <article-title>Consequences of the expanding global distribution of <italic>Aedes albopictus</italic> for dengue virus transmission</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2010</year>;<volume>4</volume>: <fpage>e646</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0000646">10.1371/journal.pntd.0000646</ext-link></comment>
<?supplied-pmid 20520794?><pub-id pub-id-type="pmid">20520794</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Sabin</surname><given-names>AB</given-names></name>. <article-title>Research on dengue during World War II</article-title>. <source>Am J Trop Med Hyg</source>. <year>1952</year>;<volume>1</volume>: <fpage>30</fpage>&#x02013;<lpage>50</lpage>. <?supplied-pmid 14903434?><pub-id pub-id-type="pmid">14903434</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Reyes</surname><given-names>M</given-names></name>, <name><surname>Mercado</surname><given-names>JC</given-names></name>, <name><surname>Standish</surname><given-names>K</given-names></name>, <name><surname>Matute</surname><given-names>JC</given-names></name>, <name><surname>Ortega</surname><given-names>O</given-names></name>, <name><surname>Moraga</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Index cluster study of dengue virus infection in Nicaragua</article-title>. <source>Am J Trop Med Hyg</source>. <year>2010</year>;<volume>83</volume>: <fpage>683</fpage>&#x02013;<lpage>689</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4269/ajtmh.2010.10-0023">10.4269/ajtmh.2010.10-0023</ext-link></comment>
<?supplied-pmid 20810839?><pub-id pub-id-type="pmid">20810839</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Beckett</surname><given-names>CG</given-names></name>, <name><surname>Kosasih</surname><given-names>H</given-names></name>, <name><surname>Faisal</surname><given-names>I</given-names></name>, <name><surname>Nurhayati</surname></name>, <name><surname>Tan</surname><given-names>R</given-names></name>, <name><surname>Widjaja</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Early detection of dengue infections using cluster sampling around index cases</article-title>. <source>Am J Trop Med Hyg</source>. <year>2005</year>;<volume>72</volume>: <fpage>777</fpage>&#x02013;<lpage>782</lpage>. <?supplied-pmid 15967759?><pub-id pub-id-type="pmid">15967759</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Vaughn</surname><given-names>DW</given-names></name>, <name><surname>Green</surname><given-names>S</given-names></name>, <name><surname>Kalayanarooj</surname><given-names>S</given-names></name>, <name><surname>Innis</surname><given-names>BL</given-names></name>, <name><surname>Nimmannitya</surname><given-names>S</given-names></name>, <name><surname>Suntayakorn</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity</article-title>. <source>J Infect Dis</source>. <year>2000</year>;<volume>181</volume>: <fpage>2</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1086/315215">10.1086/315215</ext-link></comment>
<?supplied-pmid 10608744?><pub-id pub-id-type="pmid">10608744</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Murgue</surname><given-names>B</given-names></name>, <name><surname>Roche</surname><given-names>C</given-names></name>, <name><surname>Chungue</surname><given-names>E</given-names></name>, <name><surname>Deparis</surname><given-names>X</given-names></name>. <article-title>Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996&#x02013;1997 dengue-2 outbreak in French Polynesia</article-title>. <source>J Med Virol</source>. <year>2000</year>;<volume>60</volume>: <fpage>432</fpage>&#x02013;<lpage>438</lpage>. <?supplied-pmid 10686027?><pub-id pub-id-type="pmid">10686027</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Teixeira</surname><given-names>MdG</given-names></name>, <name><surname>Barreto</surname><given-names>ML</given-names></name>, <name><surname>Costa</surname></name>, <name><surname>Maria da Concei&#x000e7;&#x000e3;o</surname><given-names>N</given-names></name>, <name><surname>Ferreira</surname><given-names>LDA</given-names></name>, <name><surname>Vasconcelos</surname><given-names>PF</given-names></name>, <name><surname>Cairncross</surname><given-names>S</given-names></name>. <article-title>Dynamics of dengue virus circulation: a silent epidemic in a complex urban area</article-title>. <source>Trop Med Int Health</source>. <year>2002</year>;<volume>7</volume>: <fpage>757</fpage>&#x02013;<lpage>762</lpage>. <?supplied-pmid 12225506?><pub-id pub-id-type="pmid">12225506</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Duong</surname><given-names>V</given-names></name>, <name><surname>Lambrechts</surname><given-names>L</given-names></name>, <name><surname>Paul</surname><given-names>RE</given-names></name>, <name><surname>Ly</surname><given-names>S</given-names></name>, <name><surname>Lay</surname><given-names>RS</given-names></name>, <name><surname>Long</surname><given-names>KC</given-names></name>, <etal>et al</etal>
<article-title>Asymptomatic humans transmit dengue virus to mosquitoes</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2015</year>;<volume>112</volume>: <fpage>14688</fpage>&#x02013;<lpage>14693</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1508114112">10.1073/pnas.1508114112</ext-link></comment>
<?supplied-pmid 26553981?><pub-id pub-id-type="pmid">26553981</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref017"><label>17</label><mixed-citation publication-type="book"><publisher-name>World Health Organization</publisher-name>
<source>Dengue guidelines for diagnosis, treatment, prevention and control</source>. 2009. <publisher-name>WHO</publisher-name>, <publisher-loc>Geneva, Switzerland</publisher-loc>
<year>2012</year>.</mixed-citation></ref><ref id="ppat.1006965.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Clapham</surname><given-names>HE</given-names></name>, <name><surname>Tricou</surname><given-names>V</given-names></name>, <name><surname>Van Vinh Chau</surname><given-names>N</given-names></name>, <name><surname>Simmons</surname><given-names>CP</given-names></name>, <name><surname>Ferguson</surname><given-names>NM</given-names></name>. <article-title>Within-host viral dynamics of dengue serotype 1 infection</article-title>. <source>J R Soc Interface</source>. <year>2014</year>;<volume>11</volume>: <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1098/rsif.2014.0094">10.1098/rsif.2014.0094</ext-link></comment>
<?supplied-pmid 24829280?><pub-id pub-id-type="pmid">24829280</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Perdomo-Celis</surname><given-names>F</given-names></name>, <name><surname>Salgado</surname><given-names>DM</given-names></name>, <name><surname>Narv&#x000e1;ez</surname><given-names>CF</given-names></name>. <article-title>Magnitude of viremia, antigenemia and infection of circulating monocytes in children with mild and severe dengue</article-title>. <source>Acta Trop</source>. <year>2017</year>;<volume>167</volume>: <fpage>1</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.actatropica.2016.12.011">10.1016/j.actatropica.2016.12.011</ext-link></comment>
<?supplied-pmid 27986543?><pub-id pub-id-type="pmid">27986543</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Duyen</surname><given-names>HT</given-names></name>, <name><surname>Ngoc</surname><given-names>TV</given-names></name>, <name><surname>Ha do</surname><given-names>T</given-names></name>, <name><surname>Hang</surname><given-names>VT</given-names></name>, <name><surname>Kieu</surname><given-names>NT</given-names></name>, <name><surname>Young</surname><given-names>PR</given-names></name>, <etal>et al</etal>
<article-title>Kinetics of plasma viremia and soluble nonstructural protein 1 concentrations in dengue: differential effects according to serotype and immune status</article-title>. <source>J Infect Dis</source>. <year>2011</year>;<volume>203</volume>: <fpage>1292</fpage>&#x02013;<lpage>1300</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/infdis/jir014">10.1093/infdis/jir014</ext-link></comment>
<?supplied-pmid 21335562?><pub-id pub-id-type="pmid">21335562</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Tricou</surname><given-names>V</given-names></name>, <name><surname>Minh</surname><given-names>NN</given-names></name>, <name><surname>Van</surname><given-names>TP</given-names></name>, <name><surname>Lee</surname><given-names>SJ</given-names></name>, <name><surname>Farrar</surname><given-names>J</given-names></name>, <name><surname>Wills</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2010</year>;<volume>4</volume>: <fpage>e785</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0000785">10.1371/journal.pntd.0000785</ext-link></comment>
<?supplied-pmid 20706626?><pub-id pub-id-type="pmid">20706626</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Olkowski</surname><given-names>S</given-names></name>, <name><surname>Forshey</surname><given-names>BM</given-names></name>, <name><surname>Morrison</surname><given-names>AC</given-names></name>, <name><surname>Rocha</surname><given-names>C</given-names></name>, <name><surname>Vilcarromero</surname><given-names>S</given-names></name>, <name><surname>Halsey</surname><given-names>ES</given-names></name>, <etal>et al</etal>
<article-title>Reduced risk of disease during postsecondary dengue virus infections</article-title>. <source>J Infect Dis</source>. <year>2013</year>;<volume>208</volume>: <fpage>1026</fpage>&#x02013;<lpage>1033</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/infdis/jit273">10.1093/infdis/jit273</ext-link></comment>
<?supplied-pmid 23776195?><pub-id pub-id-type="pmid">23776195</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Clapham</surname><given-names>HE</given-names></name>, <name><surname>Cummings</surname><given-names>DA</given-names></name>, <name><surname>Johansson</surname><given-names>MA</given-names></name>. <article-title>Immune status alters the probability of apparent illness due to dengue virus infection: Evidence from a pooled analysis across multiple cohort and cluster studies</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2017</year>;<volume>11</volume>: <fpage>e0005926</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0005926">10.1371/journal.pntd.0005926</ext-link></comment>
<?supplied-pmid 28953902?><pub-id pub-id-type="pmid">28953902</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Stanaway</surname><given-names>JD</given-names></name>, <name><surname>Shepard</surname><given-names>DS</given-names></name>, <name><surname>Undurraga</surname><given-names>EA</given-names></name>, <name><surname>Halasa</surname><given-names>YA</given-names></name>, <name><surname>Coffeng</surname><given-names>LE</given-names></name>, <name><surname>Brady</surname><given-names>OJ</given-names></name>, <etal>et al</etal>
<article-title>The global burden of dengue: an analysis from the Global Burden of Disease Study 2013</article-title>. <source>The Lancet Infect Dis</source>. <year>2016</year>;<volume>16</volume>: <fpage>712</fpage>&#x02013;<lpage>723</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1473-3099(16)00026-8">10.1016/S1473-3099(16)00026-8</ext-link></comment>
<?supplied-pmid 26874619?><pub-id pub-id-type="pmid">26874619</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref025"><label>25</label><mixed-citation publication-type="book"><name><surname>Anderson</surname><given-names>RM</given-names></name>, <name><surname>May</surname><given-names>RM</given-names></name>. <source>Infectious diseases of humans: dynamics and control</source>. <edition>1st</edition> ed: <publisher-name>Wiley Online Library</publisher-name>; <year>1992</year>.</mixed-citation></ref><ref id="ppat.1006965.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Reiner</surname><given-names>RC</given-names></name>, <name><surname>Stoddard</surname><given-names>ST</given-names></name>, <name><surname>Forshey</surname><given-names>BM</given-names></name>, <name><surname>King</surname><given-names>AA</given-names></name>, <name><surname>Ellis</surname><given-names>AM</given-names></name>, <name><surname>Lloyd</surname><given-names>AL</given-names></name>, <etal>et al</etal>
<article-title>Time-varying, serotype-specific force of infection of dengue virus</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2014</year>: 201314933.</mixed-citation></ref><ref id="ppat.1006965.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Homma</surname><given-names>T</given-names></name>, <name><surname>Saltelli</surname><given-names>A</given-names></name>. <article-title>Importance measures in global sensitivity analysis of nonlinear models</article-title>. <source>Reliab Eng Syst Saf</source>. <year>1996</year>;<volume>52</volume>: <fpage>1</fpage>&#x02013;<lpage>17</lpage>.</mixed-citation></ref><ref id="ppat.1006965.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Montoya</surname><given-names>M</given-names></name>, <name><surname>Gresh</surname><given-names>L</given-names></name>, <name><surname>Mercado</surname><given-names>JC</given-names></name>, <name><surname>Williams</surname><given-names>KL</given-names></name>, <name><surname>Vargas</surname><given-names>MJ</given-names></name>, <name><surname>Gutierrez</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2013</year>;<volume>7</volume>: <fpage>e2357</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0002357">10.1371/journal.pntd.0002357</ext-link></comment>
<?supplied-pmid 23951377?><pub-id pub-id-type="pmid">23951377</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Fraser</surname><given-names>C</given-names></name>, <name><surname>Riley</surname><given-names>S</given-names></name>, <name><surname>Anderson</surname><given-names>RM</given-names></name>, <name><surname>Ferguson</surname><given-names>NM</given-names></name>. <article-title>Factors that make an infectious disease outbreak controllable</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2004</year>;<volume>101</volume>: <fpage>6146</fpage>&#x02013;<lpage>6151</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.0307506101">10.1073/pnas.0307506101</ext-link></comment>
<?supplied-pmid 15071187?><pub-id pub-id-type="pmid">15071187</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Thompson</surname><given-names>RN</given-names></name>, <name><surname>Gilligan</surname><given-names>CA</given-names></name>, <name><surname>Cunniffe</surname><given-names>NJ</given-names></name>. <article-title>Detecting Presymptomatic Infection Is Necessary to Forecast Major Epidemics in the Earliest Stages of Infectious Disease Outbreaks</article-title>. <source>PLoS Comput Biol</source>. <year>2016</year>;<volume>12</volume>: <fpage>e1004836</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pcbi.1004836">10.1371/journal.pcbi.1004836</ext-link></comment>
<?supplied-pmid 27046030?><pub-id pub-id-type="pmid">27046030</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Flasche</surname><given-names>S</given-names></name>, <name><surname>Jit</surname><given-names>M</given-names></name>, <name><surname>Rodr&#x000ed;guez-Barraquer</surname><given-names>I</given-names></name>, <name><surname>Coudeville</surname><given-names>L</given-names></name>, <name><surname>Recker</surname><given-names>M</given-names></name>, <name><surname>Koelle</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): a model comparison study</article-title>. <source>PLoS medicine</source>. <year>2016</year>;<volume>13</volume>: <fpage>e1002181</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pmed.1002181">10.1371/journal.pmed.1002181</ext-link></comment>
<?supplied-pmid 27898668?><pub-id pub-id-type="pmid">27898668</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Ferguson</surname><given-names>NM</given-names></name>, <name><surname>Rodr&#x000ed;guez-Barraquer</surname><given-names>I</given-names></name>, <name><surname>Dorigatti</surname><given-names>I</given-names></name>, <name><surname>Mier-y-Teran-Romero</surname><given-names>L</given-names></name>, <name><surname>Laydon</surname><given-names>DJ</given-names></name>, <name><surname>Cummings</surname><given-names>DA</given-names></name>. <article-title>Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment</article-title>. <source>Science</source>. <year>2016</year>;<volume>353</volume>: <fpage>1033</fpage>&#x02013;<lpage>1036</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.aaf9590">10.1126/science.aaf9590</ext-link></comment>
<?supplied-pmid 27701113?><pub-id pub-id-type="pmid">27701113</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Vazquez-Prokopec</surname><given-names>GM</given-names></name>, <name><surname>Perkins</surname><given-names>TA</given-names></name>, <name><surname>Waller</surname><given-names>LA</given-names></name>, <name><surname>Lloyd</surname><given-names>AL</given-names></name>, <name><surname>Reiner</surname><given-names>RC</given-names></name>, <name><surname>Scott</surname><given-names>TW</given-names></name>, <etal>et al</etal>
<article-title>Coupled Heterogeneities and Their Impact on Parasite Transmission and Control</article-title>. <source>Trends Parasitol</source>. <year>2016</year>;<volume>32</volume>: <fpage>356</fpage>&#x02013;<lpage>367</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.pt.2016.01.001">10.1016/j.pt.2016.01.001</ext-link></comment>
<?supplied-pmid 26850821?><pub-id pub-id-type="pmid">26850821</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref034"><label>34</label><mixed-citation publication-type="book"><name><surname>Perkins</surname><given-names>TA</given-names></name>, <name><surname>Reiner</surname><given-names>RC</given-names><suffix>Jr</suffix></name>, <name><surname>Rodriguez-Barraquer</surname><given-names>I</given-names></name>, <name><surname>Smith</surname><given-names>DL</given-names></name>, <name><surname>Scott</surname><given-names>TW</given-names></name>, <name><surname>Cummings</surname><given-names>DA</given-names></name>. <chapter-title>A Review of Transmission Models of Dengue: A Quantitative and Qualitative Analysis of Model Features</chapter-title> In: <name><surname>Gubler</surname><given-names>DJ</given-names></name>, <name><surname>Ooi</surname><given-names>EE</given-names></name>, <name><surname>Vasudevan</surname><given-names>S</given-names></name>, <name><surname>Farrar</surname><given-names>J</given-names></name>, editors. <source>Dengue and Dengue Hemorrhagic Fever</source>
<edition>2nd</edition> Edition. <publisher-loc>Oxfordshire</publisher-loc>: <publisher-name>CABI</publisher-name>; <year>2015</year> pp. <fpage>99</fpage>&#x02013;<lpage>114</lpage>.</mixed-citation></ref><ref id="ppat.1006965.ref035"><label>35</label><mixed-citation publication-type="other">World Health Organization. SAGE April 2016. 2016.</mixed-citation></ref><ref id="ppat.1006965.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Rodriguez-Barraquer</surname><given-names>I</given-names></name>, <name><surname>Mier-y-Teran-Romero</surname><given-names>L</given-names></name>, <name><surname>Burke</surname><given-names>DS</given-names></name>, <name><surname>Cummings</surname><given-names>DA</given-names></name>. <article-title>Challenges in the interpretation of dengue vaccine trial results</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2013</year>;<volume>7</volume>: <fpage>e2126</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0002126">10.1371/journal.pntd.0002126</ext-link></comment>
<?supplied-pmid 24009782?><pub-id pub-id-type="pmid">24009782</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Hadinegoro</surname><given-names>SR</given-names></name>, <name><surname>Arredondo-Garc&#x000ed;a</surname><given-names>JL</given-names></name>, <name><surname>Capeding</surname><given-names>MR</given-names></name>, <name><surname>Deseda</surname><given-names>C</given-names></name>, <name><surname>Chotpitayasunondh</surname><given-names>T</given-names></name>, <name><surname>Dietze</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Efficacy and long-term safety of a dengue vaccine in regions of endemic disease</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>373</volume>: <fpage>1195</fpage>&#x02013;<lpage>1206</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa1506223">10.1056/NEJMoa1506223</ext-link></comment>
<?supplied-pmid 26214039?><pub-id pub-id-type="pmid">26214039</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Ben-Shachar</surname><given-names>R</given-names></name>, <name><surname>Schmidler</surname><given-names>S</given-names></name>, <name><surname>Koelle</surname><given-names>K</given-names></name>. <article-title>Drivers of Inter-individual Variation in Dengue Viral Load Dynamics</article-title>. <source>PLoS Comput Biol</source>. <year>2016</year>;<volume>12</volume>: <fpage>e1005194</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pcbi.1005194">10.1371/journal.pcbi.1005194</ext-link></comment>
<?supplied-pmid 27855153?><pub-id pub-id-type="pmid">27855153</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Reiner</surname><given-names>RC</given-names></name>, <name><surname>Stoddard</surname><given-names>ST</given-names></name>, <name><surname>Scott</surname><given-names>TW</given-names></name>. <article-title>Socially structured human movement shapes dengue transmission despite the diffusive effect of mosquito dispersal</article-title>. <source>Epidemics</source>. <year>2014</year>;<volume>6</volume>: <fpage>30</fpage>&#x02013;<lpage>36</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.epidem.2013.12.003">10.1016/j.epidem.2013.12.003</ext-link></comment>
<?supplied-pmid 24593919?><pub-id pub-id-type="pmid">24593919</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Clapham</surname><given-names>HE</given-names></name>, <name><surname>Quyen</surname><given-names>TH</given-names></name>, <name><surname>Kien</surname><given-names>DTH</given-names></name>, <name><surname>Dorigatti</surname><given-names>I</given-names></name>, <name><surname>Simmons</surname><given-names>CP</given-names></name>, <name><surname>Ferguson</surname><given-names>NM</given-names></name>. <article-title>Modelling Virus and Antibody Dynamics during Dengue Virus Infection Suggests a Role for Antibody in Virus Clearance</article-title>. <source>PLoS Comput Biol</source>. <year>2016</year>;<volume>12</volume>: <fpage>e1004951</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pcbi.1004951">10.1371/journal.pcbi.1004951</ext-link></comment>
<?supplied-pmid 27213681?><pub-id pub-id-type="pmid">27213681</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Nguyen</surname><given-names>MN</given-names></name>, <name><surname>Duong</surname><given-names>TH</given-names></name>, <name><surname>Trung</surname><given-names>VT</given-names></name>, <name><surname>Nguyen</surname><given-names>TH</given-names></name>, <name><surname>Tran</surname><given-names>CN</given-names></name>, <name><surname>Long</surname><given-names>VT</given-names></name>, <etal>et al</etal>
<article-title>Host and viral features of human dengue cases shape the population of infected and infectious <italic>Aedes aegypti</italic> mosquitoes</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2013</year>;<volume>110</volume>: <fpage>9072</fpage>&#x02013;<lpage>9077</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1303395110">10.1073/pnas.1303395110</ext-link></comment>
<?supplied-pmid 23674683?><pub-id pub-id-type="pmid">23674683</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Ferguson</surname><given-names>NM</given-names></name>, <name><surname>Kien</surname><given-names>DT</given-names></name>, <name><surname>Clapham</surname><given-names>H</given-names></name>, <name><surname>Aguas</surname><given-names>R</given-names></name>, <name><surname>Trung</surname><given-names>VT</given-names></name>, <name><surname>Chau</surname><given-names>TN</given-names></name>, <etal>et al</etal>
<article-title>Modeling the impact on virus transmission of Wolbachia-mediated blocking of dengue virus infection of <italic>Aedes aegypti</italic></article-title>. <source>Sci Transl Med</source>. <year>2015</year>;<volume>7</volume>: <fpage>279ra37</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/scitranslmed.3010370">10.1126/scitranslmed.3010370</ext-link></comment>
<?supplied-pmid 25787763?><pub-id pub-id-type="pmid">25787763</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Carrington</surname><given-names>LB</given-names></name>, <name><surname>Tran</surname><given-names>BCN</given-names></name>, <name><surname>Le</surname><given-names>NTH</given-names></name>, <name><surname>Luong</surname><given-names>TTH</given-names></name>, <name><surname>Nguyen</surname><given-names>TT</given-names></name>, <name><surname>Nguyen</surname><given-names>PT</given-names></name>, <etal>et al</etal>
<article-title>Field- and clinically derived estimates of Wolbachia-mediated blocking of dengue virus transmission potential in <italic>Aedes aegypti</italic> mosquitoes</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2018</year>;<volume>115</volume>: <fpage>361</fpage>&#x02013;<lpage>366</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1715788115">10.1073/pnas.1715788115</ext-link></comment>
<?supplied-pmid 29279375?><pub-id pub-id-type="pmid">29279375</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>ten Bosch</surname><given-names>QA</given-names></name>, <name><surname>Singh</surname><given-names>BK</given-names></name>, <name><surname>Hassan</surname><given-names>MR</given-names></name>, <name><surname>Chadee</surname><given-names>DD</given-names></name>, <name><surname>Michael</surname><given-names>E</given-names></name>. <article-title>The Role of Serotype Interactions and Seasonality in Dengue Model Selection and Control: Insights from a Pattern Matching Approach</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2016</year>;<volume>10</volume>: <fpage>e0004680</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0004680">10.1371/journal.pntd.0004680</ext-link></comment>
<?supplied-pmid 27159023?><pub-id pub-id-type="pmid">27159023</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Guzm&#x000e1;n</surname><given-names>MG</given-names></name>, <name><surname>Kour&#x00131;&#x000ed;</surname><given-names>G</given-names></name>. <article-title>Dengue diagnosis, advances and challenges</article-title>. <source>Int J of Inf Dis</source>. <year>2004</year>;<volume>8</volume>: <fpage>69</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">14732325</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Perkins</surname><given-names>TA</given-names></name>, <name><surname>Paz-Soldan</surname><given-names>VA</given-names></name>, <name><surname>Stoddard</surname><given-names>ST</given-names></name>, <name><surname>Morrison</surname><given-names>AC</given-names></name>, <name><surname>Forshey</surname><given-names>BM</given-names></name>, <name><surname>Long</surname><given-names>KC</given-names></name>, <etal>et al</etal>
<article-title>Calling in sick: impacts of fever on intra-urban human mobility</article-title>. <source>Proc Biol Sci</source>. <year>2016</year>;<volume>283</volume>: <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1098/rspb.2016.0390">10.1098/rspb.2016.0390</ext-link></comment>
<?supplied-pmid 27412286?><pub-id pub-id-type="pmid">27412286</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Restif</surname><given-names>O</given-names></name>, <name><surname>Graham</surname><given-names>AL</given-names></name>. <article-title>Within-host dynamics of infection: from ecological insights to evolutionary predictions</article-title>. <source>Philos Trans R Soc Lond B Biol Sci</source>. <year>2015</year>;<volume>370</volume>: <fpage>1675</fpage>.</mixed-citation></ref><ref id="ppat.1006965.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Handel</surname><given-names>A</given-names></name>, <name><surname>Rohani</surname><given-names>P</given-names></name>. <article-title>Crossing the scale from within-host infection dynamics to between-host transmission fitness: a discussion of current assumptions and knowledge</article-title>. <source>Philos Trans R Soc Lond B Biol Sci</source>. <year>2015</year>;<volume>370</volume>: <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1098/rstb.2014.0302">10.1098/rstb.2014.0302</ext-link></comment>
<?supplied-pmid 26150668?><pub-id pub-id-type="pmid">26150668</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Duong</surname><given-names>V</given-names></name>, <name><surname>Ly</surname><given-names>S</given-names></name>, <name><surname>Try</surname><given-names>PL</given-names></name>, <name><surname>Tuiskunen</surname><given-names>A</given-names></name>, <name><surname>Ong</surname><given-names>S</given-names></name>, <name><surname>Chroeung</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Clinical and virological factors influencing the performance of a NS1 antigen-capture assay and potential use as a marker of dengue disease severity</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2011</year>;<volume>5</volume>: <fpage>e1244</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0001244">10.1371/journal.pntd.0001244</ext-link></comment>
<?supplied-pmid 21811645?><pub-id pub-id-type="pmid">21811645</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Rodriguez-Barraquer</surname><given-names>I</given-names></name>, <name><surname>Cordeiro</surname><given-names>MT</given-names></name>, <name><surname>Braga</surname><given-names>C</given-names></name>, <name><surname>de Souza</surname><given-names>WV</given-names></name>, <name><surname>Marques</surname><given-names>ET</given-names></name>, <name><surname>Cummings</surname><given-names>D</given-names></name>. <article-title>From re-emergence to hyperendemicity: the natural history of the dengue epidemic in Brazil</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2011</year>;<volume>5</volume>: <fpage>e935</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0000935">10.1371/journal.pntd.0000935</ext-link></comment>
<?supplied-pmid 21245922?><pub-id pub-id-type="pmid">21245922</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref051"><label>51</label><mixed-citation publication-type="other">Yearbook D. United Nations Statistics Division. Statistical Dissemination Section, New York. 2010.</mixed-citation></ref><ref id="ppat.1006965.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Alera</surname><given-names>MT</given-names></name>, <name><surname>Srikiatkhachorn</surname><given-names>A</given-names></name>, <name><surname>Velasco</surname><given-names>JM</given-names></name>, <name><surname>Tac-An</surname><given-names>IA</given-names></name>, <name><surname>Lago</surname><given-names>CB</given-names></name>, <name><surname>Clapham</surname><given-names>HE</given-names></name>, <etal>et al</etal>
<article-title>Incidence of dengue virus infection in adults and children in a prospective longitudinal cohort in the Philippines</article-title>. <source>PLoS neglected tropical diseases</source>. <year>2016</year>;<volume>10</volume>: <fpage>e0004337</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0004337">10.1371/journal.pntd.0004337</ext-link></comment>
<?supplied-pmid 26845762?><pub-id pub-id-type="pmid">26845762</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Dayan</surname><given-names>G</given-names></name>, <name><surname>Arredondo</surname><given-names>JL</given-names></name>, <name><surname>Carrasquilla</surname><given-names>G</given-names></name>, <name><surname>Deseda</surname><given-names>CC</given-names></name>, <name><surname>Dietze</surname><given-names>R</given-names></name>, <name><surname>Luz</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Prospective cohort study with active surveillance for fever in four dengue endemic countries in Latin America</article-title>. <source>Am J Trop Med Hyg</source>. <year>2015</year>;<volume>93</volume>: <fpage>18</fpage>&#x02013;<lpage>23</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4269/ajtmh.13-0663">10.4269/ajtmh.13-0663</ext-link></comment>
<?supplied-pmid 26013373?><pub-id pub-id-type="pmid">26013373</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Balmaseda</surname><given-names>A</given-names></name>, <name><surname>Standish</surname><given-names>K</given-names></name>, <name><surname>Mercado</surname><given-names>JC</given-names></name>, <name><surname>Matute</surname><given-names>JC</given-names></name>, <name><surname>Tellez</surname><given-names>Y</given-names></name>, <name><surname>Saborio</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua</article-title>. <source>J Infect Dis</source>. <year>2010</year>;<volume>201</volume>: <fpage>5</fpage>&#x02013;<lpage>14</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1086/648592">10.1086/648592</ext-link></comment>
<?supplied-pmid 19929380?><pub-id pub-id-type="pmid">19929380</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Tissera</surname><given-names>H</given-names></name>, <name><surname>Amarasinghe</surname><given-names>A</given-names></name>, <name><surname>De Silva</surname><given-names>AD</given-names></name>, <name><surname>Kariyawasam</surname><given-names>P</given-names></name>, <name><surname>Corbett</surname><given-names>KS</given-names></name>, <name><surname>Katzelnick</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Burden of dengue infection and disease in a pediatric cohort in urban Sri Lanka</article-title>. <source>Am J Trop Med Hyg</source>. <year>2014</year>;<volume>91</volume>: <fpage>132</fpage>&#x02013;<lpage>137</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4269/ajtmh.13-0540">10.4269/ajtmh.13-0540</ext-link></comment>
<?supplied-pmid 24865684?><pub-id pub-id-type="pmid">24865684</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Tien</surname><given-names>NTK</given-names></name>, <name><surname>Luxemburger</surname><given-names>C</given-names></name>, <name><surname>Toan</surname><given-names>NT</given-names></name>, <name><surname>Pollissard-Gadroy</surname><given-names>L</given-names></name>, <name><surname>Huong</surname><given-names>VTQ</given-names></name>, <name><surname>Van Be</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>A prospective cohort study of dengue infection in schoolchildren in Long Xuyen, Viet Nam</article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>2010</year>;<volume>104</volume>: <fpage>592</fpage>&#x02013;<lpage>600</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.trstmh.2010.06.003">10.1016/j.trstmh.2010.06.003</ext-link></comment>
<?supplied-pmid 20630553?><pub-id pub-id-type="pmid">20630553</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Burke</surname><given-names>DS</given-names></name>, <name><surname>Nisalak</surname><given-names>A</given-names></name>, <name><surname>Johnson</surname><given-names>DE</given-names></name>, <name><surname>Scott</surname><given-names>RM</given-names></name>. <article-title>A prospective study of dengue infections in Bangkok</article-title>. <source>Am J Trop Med Hyg</source>. <year>1988</year>;<volume>38</volume>: <fpage>172</fpage>&#x02013;<lpage>180</lpage>. <?supplied-pmid 3341519?><pub-id pub-id-type="pmid">3341519</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Yoon</surname><given-names>IK</given-names></name>, <name><surname>Rothman</surname><given-names>AL</given-names></name>, <name><surname>Tannitisupawong</surname><given-names>D</given-names></name>, <name><surname>Srikiatkhachorn</surname><given-names>A</given-names></name>, <name><surname>Jarman</surname><given-names>RG</given-names></name>, <name><surname>Aldstadt</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Underrecognized mildly symptomatic viremic dengue virus infections in rural Thai schools and villages</article-title>. <source>J Infect Dis</source>. <year>2012</year>;<volume>206</volume>: <fpage>389</fpage>&#x02013;<lpage>398</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/infdis/jis357">10.1093/infdis/jis357</ext-link></comment>
<?supplied-pmid 22615312?><pub-id pub-id-type="pmid">22615312</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Arg&#x000fc;ello</surname><given-names>DF</given-names></name>, <name><surname>Tomashek</surname><given-names>KM</given-names></name>, <name><surname>Qui&#x000f1;ones</surname><given-names>L</given-names></name>, <name><surname>Beltran</surname><given-names>M</given-names></name>, <name><surname>Acosta</surname><given-names>L</given-names></name>, <name><surname>Santiago</surname><given-names>LM</given-names></name>, <etal>et al</etal>
<article-title>Incidence of dengue virus infection in school-aged children in Puerto Rico: A prospective seroepidemiologic study</article-title>. <source>Am J Trop Med Hyg</source>. <year>2015</year>;<volume>92</volume>: <fpage>486</fpage>&#x02013;<lpage>491</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4269/ajtmh.14-0231">10.4269/ajtmh.14-0231</ext-link></comment>
<?supplied-pmid 25646256?><pub-id pub-id-type="pmid">25646256</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref060"><label>60</label><mixed-citation publication-type="other">Stan Development Team. Stan: A C library for probability and sampling. Online: <ext-link ext-link-type="uri" xlink:href="http://mc-stan.org">http://mc-stan.org</ext-link>. 2014.</mixed-citation></ref><ref id="ppat.1006965.ref061"><label>61</label><mixed-citation publication-type="book"><name><surname>Burnham</surname><given-names>KP</given-names></name>, <name><surname>Anderson</surname><given-names>DR</given-names></name>. <source>Model selection and multimodel inference: a practical information-theoretic approach</source>: <publisher-name>Springer Science &#x00026; Business Media</publisher-name>; <year>2003</year>.</mixed-citation></ref><ref id="ppat.1006965.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>D</given-names></name>, <name><surname>McKenzie</surname><given-names>FE</given-names></name>. <article-title>Statics and dynamics of malaria infection in <italic>Anopheles</italic> mosquitoes</article-title>. <source>Malar J</source>. <year>2004</year>;<volume>3</volume>: <fpage>13</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1475-2875-3-13">10.1186/1475-2875-3-13</ext-link></comment>
<?supplied-pmid 15180900?><pub-id pub-id-type="pmid">15180900</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Nishiura</surname><given-names>H</given-names></name>, <name><surname>Halstead</surname><given-names>SB</given-names></name>. <article-title>Natural History of Dengue Virus (DENV)&#x02014;1 and DENV&#x02014;4 Infections: Reanalysis of Classic Studies</article-title>. <source>J Infect Dis</source>. <year>2007</year>;<volume>195</volume>: <fpage>1007</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1086/511825">10.1086/511825</ext-link></comment>
<?supplied-pmid 17330791?><pub-id pub-id-type="pmid">17330791</pub-id></mixed-citation></ref><ref id="ppat.1006965.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Reich</surname><given-names>NG</given-names></name>, <name><surname>Shrestha</surname><given-names>S</given-names></name>, <name><surname>King</surname><given-names>AA</given-names></name>, <name><surname>Rohani</surname><given-names>P</given-names></name>, <name><surname>Lessler</surname><given-names>J</given-names></name>, <name><surname>Kalayanarooj</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity</article-title>. <source>J R Soc Interface</source>. <year>2013</year>;<volume>10</volume>: <fpage>20130414</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1098/rsif.2013.0414">10.1098/rsif.2013.0414</ext-link></comment>
<?supplied-pmid 23825116?><pub-id pub-id-type="pmid">23825116</pub-id></mixed-citation></ref></ref-list></back></article>